UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ~~September~~March 3031, ~~2015~~2016 Commission file number 333-184233-14

ACELITY L.P. INC.

(Exact name of registrant as specified in its charter)



Guernsey		98-1022387
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

12930 West Interstate 10 San Antonio, Texas		78249
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (210) 524-9000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.



Yes	X	No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).



Yes	X	No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer			Accelerated filer

Non-accelerated filer	X	(Do not check if a smaller reporting company)	Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



Yes	No	X

As of ~~October~~May 262, ~~2015~~2016, there were 341,410,891.610 Class A-1 and 717,038.800 Class A-2 partnership units outstanding, all of which were held by affiliates.

TABLE OF CONTENTS

ACELITY L.P. INC.

			Page No.
PART I.	FINANCIAL INFORMATION		4
	Item 1.	Financial Statements	4
		Condensed Consolidated Balance Sheets	4
		Condensed Consolidated Statements of Operations	5
		Condensed Consolidated Statements of Comprehensive Loss	6
		Condensed Consolidated Statements of Cash Flows	7
		Notes to Condensed Consolidated Financial Statements	8
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2729
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3741
	Item 4.	Controls and Procedures	3741
PART II.	OTHER INFORMATION		3741
	Item 1.	Legal Proceedings	3741
	Item 1A.	Risk Factors	3741
	Item 6.	Exhibits	3842
	SIGNATURES		3943

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” The forward-looking statements are based on our current expectations and projections about future events. Discussions containing forward-looking statements may be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Risk Factors,” and elsewhere in this report. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “predicts,” “projects,” “potential,” “continue,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” or the negative of those terms and other variations of them or by comparable terminology.

These forward-looking statements are only predictions, not historical facts, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. The factors that could contribute to such differences include those discussed under the caption “Risk Factors.” You should consider each of the risk factors and uncertainties under the caption “Risk Factors” in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015, among other things, in evaluating our prospects and future financial performance. The occurrence of the events described in the risk factors could harm our business, results of operations and financial condition. These forward-looking statements are made as of the date of this report. Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this report, whether as a result of new information, future events or otherwise.

TRADEMARKS, SERVICE MARKS AND COPYRIGHTS

~~3M®~~We ~~Tegaderm®~~own is a ~~licensed~~number ~~trademark~~ of 3Mregistered ~~Company;~~and ~~GRAFTJACKET®~~common islaw atrademarks ~~licensed~~and pending applications for trademark ofregistrations ~~Wright~~in ~~Medical~~the ~~Technology~~United States and other countries, primarily through our subsidiaries (including KCI Licensing, Inc;., ~~Novadaq®~~LifeCell and Systagenix Wound Management IP Co B.V.), ~~SPY®~~including: ABThera Open Abdomen Negative Pressure Therapy, AlloDerm Regenerative Tissue Matrix, AlloDerm RTU Regenerative Tissue Matrix, Strattice Reconstructive Tissue Matrix, Revolve System, Prevena Incision Management System, PROMOGRAN Matrix Wound Dressing, TIELLE Hydropolymer Adhesive Dressing, ADAPTIC Non-Adhering Dressing, V.A.C. Therapy, V.A.C. GranuFoam Dressing, CelluTome Epidermal Harvesting System, SNaP Therapy System and ~~SPY~~iOn ~~ELITE®~~Healing Mobile App. Unless otherwise indicated, all trademarks appearing in this Quarterly Report on Form 10-Q are ~~licensed~~proprietary to us, our affiliates and/or licensors. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of ~~Novadaq~~other ~~Technologies~~companies, which to our knowledge are the property of their respective owners. For example, 3M Tegaderm is a licensed trademark of 3M Company; GRAFTJACKET is a licensed trademark of Wright Medical Technology Inc.; and Prontosan® Wound Irrigation Solution is a licensed trademark of B. Braun Medical, Inc. ~~Unless~~Solely ~~otherwise~~for ~~indicated~~convenience, ~~all~~the ~~other~~ trademarks, ~~appearing~~tradenames and service marks referred to in this ~~report~~Quarterly Report on Form 10-Q may appear without the ®, ™ and SM symbols, but such references are ~~proprietary~~not intended to ~~KCI Licensing~~indicate, ~~Inc.~~in any way, ~~LifeCell~~that ~~Corporation~~we orwill ~~Systagenix~~not ~~Wound~~assert, ~~Management~~to IPthe Cofullest ~~B.V.~~extent under applicable law, ~~their~~our ~~affiliates~~rights ~~and/~~or ~~licensors.~~the ~~The~~rights ~~absence~~ of athe ~~trademark~~applicable orlicensors ~~service~~to ~~mark~~these ortrademarks, ~~logo~~tradenames ~~from~~and ~~this~~service ~~report~~marks. ~~does~~We do not ~~constitute~~intend aour ~~waiver~~use ofor ~~trademark~~display orof other ~~intellectual~~parties’ ~~property~~trademarks, ~~rights~~trade ofnames ~~KCI~~or ~~Licensing,~~service ~~Inc.~~marks to imply, ~~Systagenix~~and ~~Wound~~such ~~Management~~use IPor Codisplay ~~B.V.~~should not be construed to imply, ora ~~LifeCell~~relationship ~~Corporation~~with, ~~their~~or ~~affiliates~~endorsement ~~and/~~or ~~licensors~~sponsorship of us by, these other parties.

DEFINED TERMS

The following terms are used in this Quarterly Report on Form 10-Q unless otherwise noted or indicated by the context.

• ~~the~~“Acelity,” ~~terms~~ the “Company,” “we,” “~~our,~~us” and “usour” ~~refer~~mean to Acelity L.P. Inc. ~~(“Acelity”)~~ and its consolidated subsidiaries.;

• ~~the~~The ~~term~~ “~~Merger~~2011 LBO” ~~refers~~means to the ~~transaction~~acquisition ~~completed~~of ~~on November 4~~KCI, ~~2011~~LifeCell ~~pursuant~~and totheir ~~which~~respective ~~Kinetic~~subsidiaries ~~Concepts,~~by ~~Inc.~~the ~~was~~Sponsors ~~merged~~and ~~with~~the ~~Chiron~~corporate ~~Merger~~reorganization ~~Sub,~~which ~~Inc.~~resulted ~~(“Merger~~in ~~Sub”)~~LifeCell Corporation, formerly a ~~direct~~100% owned subsidiary of ~~Chiron~~Kinetic ~~Holdings~~Concepts, Inc., ~~(“Holdings”)~~becoming ~~and~~a ansister ~~indirect~~corporation ~~subsidiary~~ of ~~Acelity~~Kinetic ~~L.P.~~Concepts, Inc., which was completed on November 4, 2011;


•	the term “KCI” means Kinetic Concepts, Inc. and its subsidiaries.


•	the term “LifeCell” means LifeCell Corporation and its subsidiaries.


•	the term “Systagenix” means “Systagenix Wound Management B.V., its subsidiaries, and its former U.S.-based affiliate, Systagenix Wound Management (US), Inc.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands)

	September 30, 2015			December 31, 2014
	March 31, 2016			December 31, 2015
	(unaudited)
Assets:
Current assets:
Cash and cash equivalents	$	~~197~~223,~~010~~616		$	~~183~~88,~~541~~409
Accounts receivable, net	~~383~~419,~~438~~883			~~370~~413,~~483~~531
Inventories, net	~~182~~188,~~152~~800			~~178~~181,~~222~~309
Deferred income taxes	2743,~~699~~781			6374,~~025~~521
Prepaid expenses and other	4329,~~121~~864			2734,~~563~~985
Total current assets	~~833~~905,~~420~~944			~~822~~792,~~834~~755
Net property, plant and equipment	~~270~~266,~~077~~008			~~288~~273,~~048~~076
Debt issuance costs, net	59,998			77,896
Deferred income taxes	24,262			29,909
Deferred income taxes	26,705			31,692
Goodwill	3,406,475			3,405,823
Goodwill	3,378,298			3,378,298
Identifiable intangible assets, net	2,178,864			2,219,088
Identifiable intangible assets, net	2,270,324			2,397,251
Other non-current assets	4,647			6,104
Other non-current assets	4,772			4,694
	$	6,786,200		$	6,726,755
	$	6,843,594		$	7,000,713
Liabilities and Equity:
Current liabilities:
Accounts payable	$	5152,~~120~~666		$	5157,~~827~~910
Accrued expenses and other	~~405~~420,~~631~~204			~~343~~373,~~484~~440
Current installments of long-term debt	2522,~~388~~258			2522,~~721~~130
Income taxes payable	38,837			13,~~305~~561
Deferred income taxes	44113,~~928~~595			113,~~658~~595
Total current liabilities	~~527~~617,~~070~~560			~~535~~570,~~995~~636
Long-term debt, net of current installments and discount	4,780,663			4,815,290
Long-term debt, net of current installments, discount and debt issuance costs	4,820,113			4,720,363
Non-current tax liabilities	3433,~~386~~694			3334,~~300~~833
Deferred income taxes	~~798~~698,~~417~~471			~~792~~760,~~157~~737
Other non-current liabilities	8234,~~951~~609			~~163~~37,~~258~~021
Total liabilities	6,~~223~~204,~~487~~447			6,~~340~~123,~~000~~590
Equity:
General partner’s capital	—			—
Limited partners’ capital	~~638~~597,~~114~~389			~~670~~622,~~787~~899
Accumulated other comprehensive loss, net	(1815,~~007~~636		)	(1019,~~074~~734		)
Total equity	~~620~~581,~~107~~753			~~660~~603,~~713~~165
	$	6,~~843~~786,~~594~~200		$	76,~~000~~726,~~713~~755

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands)

(unaudited)

	Three months ended September 30,						Nine months ended September 30,
	Three months ended March 31,
	2015			2014			2015			2014
	2016			2015
Revenue:
Rental	$	~~185~~170,~~952~~099		$	~~188~~172,~~843~~839		$	~~539,188~~		$	~~527,449~~
Sales	~~291~~281,~~728~~267			~~292~~271,~~950~~211			~~844,187~~			~~856,157~~
Total revenue	~~477~~451,~~680~~366			~~481~~444,~~793~~050			~~1,383,375~~			~~1,383,606~~
Rental expenses	7674,~~625~~895			8378,~~581~~178			~~232,672~~			~~254,119~~
Cost of sales	7678,~~929~~579			8373,~~799~~414			~~225,852~~			~~245,271~~
Gross profit	~~324~~297,~~126~~892			~~314~~292,~~413~~458			~~924,851~~			~~884,216~~
Selling, general and administrative expenses	~~159~~164,~~956~~444			~~162~~147,~~269~~763			~~466,713~~			~~507,646~~
Research and development expenses	1413,~~271~~978			1514,~~879~~678			~~43,340~~			~~51,602~~
Acquired intangible asset amortization	4342,~~845~~202			4745,~~918~~877			~~134,434~~			~~147,361~~
Wake Forest settlement	—			—			—			198,578
Operating earnings	77,268			84,140
Operating earnings (loss)	106,054			88,347			280,364			(20,971		)
Interest income and other	107			147
Interest income and other	68			23			282			245
Interest expense	(108,552		)	(104,726		)
Interest expense	(106,609		)	(104,475		)	(318,709		)	(308,475		)
Loss on extinguishment of debt	(3,609		)	—
Foreign currency gain (loss)	(94,~~189~~330		)	919,~~599~~400			~~3,412~~			~~13,687~~
Derivative instruments gain (loss)	(869		)	1,630			(5,136		)	(2,670		)
Derivative instruments loss	(682		)	(3,348		)
Loss from continuing operations before income tax expense (benefit)	(10,545		)	(4,876		)	(39,787		)	(318,184		)
Loss before income tax expense (benefit)	(39,798		)	(4,387		)
Income tax benefit	(593		)	(1,641		)	(7,673		)	(114,066		)
Income tax expense (benefit)	(13,823		)	144
Loss from continuing operations	(9,952		)	(3,235		)	(32,114		)	(204,118		)
Net loss	$	(25,975	)	$	(4,531	)
Earnings from discontinued operations, net of tax	—			1,398			—			3,181
Net loss	$	(9,952	)	$	(1,837	)	$	(32,114	)	$	(200,937	)

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(unaudited)

	Three months ended September 30,						Nine months ended September 30,
	Three months ended March 31,
	2015			2014			2015			2014
	2016			2015
Net loss	$	(925,~~952~~975	)	$	(14,~~837~~531	)	$	~~(32,114~~	)	$	~~(200,937~~	)
Unrealized investment loss, net of tax benefit of $411 and $412 in 2014	—			(657		)	—			(659		)
Foreign currency translation adjustment, net of tax benefit (expense) of $755 in 2016 and ($635) in 2015	4,098			(7,071		)
Foreign currency translation adjustment, net of tax benefit (expense) of $475 and $(478) in 2015 and $(279) and $(782) in 2014	(5,797		)	(3,425		)	(7,933		)	(3,238		)
Total comprehensive loss	$	(21,877	)	$	(11,602	)
Total comprehensive loss	$	(15,749	)	$	(5,919	)	$	(40,047	)	$	(204,834	)

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(in thousands)(unaudited)
	Nine months ended September 30,
	Three months ended March 31,
	2015			2014
	2016			2015
Cash flows from operating activities:
Net loss	$	(3225,~~114~~975	)	$	(~~200~~4,~~937~~531	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Amortization of debt issuance costs and discount	3010,~~717~~107			299,~~179~~968
Depreciation and other amortization	~~197~~64,~~158~~734			~~234~~66,~~514~~331
Amortization of fair value step-up in inventory	—			6,680
Loss on disposition of assets	576			678
Provision for bad debt	5,465			11,613
Amortization of fair value step-up in inventory	164			—
Equity-based compensation expense	2,366			2,966
Provision for bad debt	2,183			1,827
Deferred income tax benefit	(24,586		)	(127,799		)
Loss on extinguishment of debt	3,609			—
Unrealized gain on derivative instruments	(5,978		)	(9,310		)
Equity-based compensation expense	768			535
Unrealized gain on foreign currency	(9,537		)	(27,559		)
Deferred income tax benefit	(24,076		)	(11,971		)
Unrealized gain on derivative instruments	(2,812		)	(315		)
Unrealized loss (gain) on foreign currency	5,327			(32,429		)
Change in assets and liabilities:
Decrease (increase) in accounts receivable, net	(157,~~889~~694		)	265,~~065~~362
Increase in inventories, net	(~~15,751~~416		)	(93,~~275~~666		)
Decrease (increase) in prepaid expenses and other	~~(15~~5,~~660~~121		)	~~12,341~~(774		)
Increase (decrease) in accounts payable	(~~545~~5,183		)	74,~~402~~363
Increase (decrease) in accrued expenses and other	(7,772		)	161,227
Increase in accrued expenses and other	49,438			56,048
Increase (decrease) in tax liabilities, net	2,~~136~~314			~~(12~~11,~~076~~525		)
Net cash provided by operating activities	~~110~~78,~~010~~185			~~105~~102,~~031~~951
Cash flows from investing activities:
Additions to property, plant and equipment	(4617,~~115~~467		)	(4610,~~760~~491		)
Increase in inventory to be converted into equipment for short-term rental	(~~2,110~~983		)	(3,~~289~~356		)
Dispositions of property, plant and equipment	~~1,917~~2			~~2,251~~—
Businesses acquired in purchase transactions, net of cash acquired	(2,948		)	(4,613		)
Increase in identifiable intangible assets and other non-current assets	(1,129		)	(1,821		)
Increase in identifiable intangible assets and other non-current assets	(5,501		)	(9,351		)
Net cash used by investing activities	(19,577		)	(15,668		)
Net cash used by investing activities	(54,757		)	(61,762		)
Cash flows from financing activities:
Distribution to limited partners	~~(55~~—		)	—(55		)
Settlement of profits interest units	(~~2,812~~217		)	(~~1,416~~517		)
Proceeds from revolving credit facility	30,000			—
Proceeds from first lien senior secured notes	400,000			—
Repayments of long-term debt and other financing obligations	(54,372		)	(19,863		)
Repayments of long-term debt and capital lease obligations	(317,731		)	(6,415		)
Debt issuance costs	(68,~~256~~407		)	—(6,256		)
Net cash used by financing activities	(33,495		)	(21,279		)
Net cash provided (used) by financing activities	73,645			(13,243		)
Effect of exchange rate changes on cash and cash equivalents	(82,~~289~~954		)	(47,~~034~~072		)
Net increase in cash and cash equivalents	13135,~~469~~207			1766,~~956~~968
Cash and cash equivalents, beginning of period	~~183~~88,~~541~~409			~~206~~183,~~949~~541
Cash and cash equivalents, end of period	$	~~197~~223,~~010~~616		$	~~224~~250,~~905~~509

See accompanying notes to condensed consolidated financial statements

Notes to Condensed Consolidated Financial Statements

NOTE 1. Summary of Significant Accounting Policies

(a) Basis of Presentation and Principles of Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP” or “the Codification”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial position and cash flows in conformity with GAAP. Operating results from interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation of our results for the interim periods presented. Certain prior period amounts have been reclassified to conform to the ~~2015~~2016 presentation.

OnThe ~~October~~Company ~~29,~~has ~~2014,~~two ~~LifeCell~~reportable ~~entered~~operating ~~into~~segments: anAdvanced ~~agreement~~Wound ~~with~~Therapeutics ~~Novadaq® Technologies Inc. (“Novadaq”) to transfer all marketing~~ and ~~distribution~~Regenerative ~~rights to the SPY® Elite System from LifeCell to Novadaq, effective November 30, 2014~~Medicine. InWe ~~connection~~also ~~with~~have ~~the~~other ~~transfer,~~revenue ~~the~~which ~~parties~~consists ~~agreed to terminate various distribution agreements entered into between 2010 and 2011. The results~~ of ~~the~~contract manufacturing operations ~~subject~~performed toat ~~the~~our ~~agreement,~~manufacturing ~~excluding~~facility ~~the~~in ~~allocation of general corporate overhead~~Gargrave, ~~are presented as discontinued operations in the condensed consolidated statements of operations for all periods presented~~England.

The condensed consolidated financial statements appearing in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

(b) Derivative Financial Instruments and Fair Value Measurements

We use derivative financial instruments to manage the economic impact of fluctuations in interest rates. We do not use financial instruments for speculative or trading purposes. Periodically, we enter into interest rate protection agreements to modify the interest characteristics of our outstanding debt. ~~Our~~As of March 31, 2016, our interest rate derivatives have not been designated as hedging instruments, and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period.

We also periodically use derivative financial instruments to manage the economic impact of fluctuations in currency exchange rates on our intercompany balances and corresponding cash flows and to manage our transactional currency exposures when our foreign subsidiaries enter into transactions denominated in currencies other than their local currency. We enter into foreign currency exchange contracts to manage these economic risks. These contracts are not designated as hedges; and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period. Although we use master netting agreements with our derivative counterparties, we do not offset derivative asset and liability positions in the condensed consolidated balance sheets.

All derivative instruments are recorded on the balance sheets at fair value. The fair values of our interest rate derivatives and foreign currency exchange contracts are determined based on inputs that are readily available in public markets or can be derived from information available in publicly-quoted markets, which represent level 2 inputs as defined by the Codification.

We have a concentration of credit risk with financial institutions related to our derivative instruments. As of ~~September~~March 3031, ~~2015~~2016, Morgan Stanley, UBS and HSBC were the counterparties on our interest rate protection agreements consisting of interest rate swap agreements in notional amounts totaling $~~478~~459.73 million each. We use master netting agreements with our derivative counterparties to reduce our risk and use multiple counterparties to reduce our concentration of credit risk.

We maintain cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits bear minimal credit risk as they are maintained at financial institutions of reputable credit and generally may be redeemed upon demand.

(d) Recently Adopted Accounting Standards

In ~~April~~January ~~2014~~2015, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU") No. ~~2014~~2015-0801, ~~“Presentation~~"Income ofStatement ~~Financial~~-Extraordinary ~~Statements (Topic 205)~~ and ~~Property,~~Unusual ~~Plant,~~Items ~~and Equipment~~ (~~Topic~~Subtopic ~~360~~225-20):." The ~~Reporting~~objective ~~Discontinued Operations and Disclosures~~ of ~~Disposals~~this ~~of Components of an Entity”.~~ ASU ~~No.~~is ~~2014-08~~to ~~changes~~simplify the ~~requirements~~income ~~for~~statement ~~reporting~~presentation ~~discontinued~~requirements ~~operations~~in ~~and~~Subtopic ~~requires~~225-20 ~~additional~~by ~~disclosures~~eliminating ~~about discontinued operations. Under~~ the ~~new~~concept ~~guidance,~~of ~~only~~extraordinary ~~disposals~~items. ~~representing~~Extraordinary aitems ~~strategic~~are ~~shift~~events inand ~~operations~~transactions - that ~~is,~~are adistinguished ~~major~~by ~~effect~~their onunusual ~~the~~nature ~~organization’s operations~~ and ~~financial~~by ~~results~~the ~~should~~infrequency ~~be presented as discontinued operations. Examples include a disposal~~ of atheir ~~major geographic area, a major line of business, or a major equity method investment~~occurrence. ~~Additionally,~~Eliminating the ~~ASU~~extraordinary ~~requires~~classification ~~expanded~~simplifies ~~disclosures~~income ~~about discontinued operations that will provide financial~~ statement ~~users~~presentation ~~with~~by ~~more~~altogether ~~information~~removing ~~about~~ the ~~assets,~~concept ~~liabilities,~~of ~~income,~~extraordinary ~~and~~items ~~expenses~~from ~~of discontinued operations~~consideration. The Company adopted this ASU effective January 1, ~~2015~~2016. We doThe ~~not~~adoption ~~anticipate~~of ~~that~~this itupdate ~~will~~did not have a material ~~effect~~impact on our results of operations, financial position or disclosures.

On February 18, 2015, the FASB issued ASU 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis." This update provides a revised consolidation model for all reporting entities to use in evaluating whether they should consolidate certain legal entities. All legal entities will be subject to reevaluation under this revised consolidation model. The revised consolidation model, among other things, (i) modifies the evaluation of whether limited partnerships and similar legal entities are variable interest entities ("VIEs") or voting interest entities, (ii) eliminates the presumption that a general partner should consolidate a limited partnership, and (iii) modifies the consolidation analysis of reporting entities that are involved with VIEs through fee arrangements and related party relationships. The Company adopted this ASU effective January 1, 2016. The adoption of this update did not have a material impact on our results of operations, financial position or disclosures.

In April 2015, the FASB issued ASU 2015-03, "Interest - Imputation of Interest (Subtopic 835-30)." The objective of this ASU was to simplify the presentation of debt issuance costs in the balance sheet by requiring the presentation of debt issuance costs as a deduction from the carrying amount of the related debt liability instead of a deferred charge. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as an asset in the balance sheet. The Company adopted this ASU effective January 1, 2016, resulting in a $54.7 million retrospective reduction of both our non-current assets and long-term debt, net of current installments, discount and debt issuance costs, as of December 31, 2015.

In September 2015, the FASB issued ASU 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments.” The amendments in this ASU require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in this ASU also require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Additionally, the amendments in this ASU require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted this ASU effective January 1, 2016. The adoption of this update did not have a material impact on our results of operations, financial position or disclosures.

(e) Recently Issued Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”.” This ASU affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition”, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts”. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, “Property, Plant, and Equipment”, and intangible assets within the scope of Topic 350, “Intangibles-Goodwill and Other”) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. In ~~July~~For ~~2015, the FASB voted to defer the effective date of this ASU by one year. As~~ a ~~result, the amendments in ASU 2014-09 are effective for~~ public ~~companies for annual reporting periods beginning after December 15~~entity, ~~2017, including interim periods within that reporting period. Entities would be permitted to adopt this ASU as early as~~ the original public entity effective date, which was annual reporting periods beginning after December 15, 2016 and interim periods therein. Early adoption prior to that date would not be permitted. The Company is evaluating ASU No. 2014-09 to determine if it will have a material effect on our results of operations, financial position or disclosures.

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements — Going Concern (Subtopic 205-40).” The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating this ASU, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In January 2015, the FASB issued ASU No. 2015-01, "Income Statement -Extraordinary and Unusual Items (Subtopic 225-20)." The objective of this ASU is to simplify the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is permitted. The Company is evaluating this ASU, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

On February 18, 2015, the FASB issued ASU 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis." This ASU provides a revised consolidation model for all reporting entities to use in evaluating whether they should consolidate certain legal entities. All legal entities will be subject to reevaluation under this revised consolidation model. The revised consolidation model, among other things, (i) modifies the evaluation of whether limited partnerships and similar legal entities are variable interest entities ("VIEs") or voting interest entities, (ii) eliminates the presumption that a general partner should consolidate a limited partnership, and (iii) modifies the consolidation analysis of reporting entities that are involved with VIEs through fee arrangements and related party relationships. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is permitted. The Company is evaluating this ASU, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

Inamendments ~~April~~in ~~2015,~~this ~~the FASB issued~~ ASU ~~2015-03,~~are ~~"Interest~~effective -for ~~Imputation~~annual ofreporting ~~Interest~~periods ~~(Subtopic~~beginning ~~835-30)." The~~after ~~objective~~December of15, ~~this~~2017, ~~ASU~~including isinterim toperiods ~~simplify~~within ~~the~~that ~~presentation~~reporting ofperiod. ~~debt~~The ~~issuance~~standard ~~costs~~may inbe ~~the~~applied ~~balance~~either ~~sheet~~retrospectively byto ~~requiring~~each ~~the~~period ~~presentation~~presented ofor ~~debt issuance costs~~ as a ~~deduction~~cumulative-effect ~~from~~adjustment ~~the~~as ~~carrying amount~~ of the ~~related~~date ~~debt liability instead~~ of ~~a deferred charge~~adoption. The ~~standard~~Company ~~will~~has benot ~~effective~~selected ~~for~~a ~~annual~~transition ~~reporting~~method ~~periods~~and ~~beginning~~we ~~after~~are ~~December~~evaluating ~~15,~~ASU ~~2015~~No. ~~Early~~ ~~adoption~~2014-09 isto ~~permitted. As~~determine ofif ~~September 30,~~it ~~2015,~~will ~~the~~have ~~Company~~a ~~had~~material ~~$60.0~~effect ~~million~~on ofour ~~unamortized~~results ~~debt~~of ~~issuance~~operations, ~~costs~~financial ~~recorded~~position asor ~~a deferred charge~~disclosures.

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements — Going Concern (Subtopic 205-40).” The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory.” The amendments in this ASU do not apply to inventory that is measured using last-in, first-out or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating this ASU, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In ~~September~~November 2015, the FASB issued ASU No. 2015-1617, “~~Business~~Income ~~Combinations~~Taxes (Topic ~~805~~740): ~~Simplifying~~Balance ~~the~~Sheet ~~Accounting~~Classification ~~for~~of ~~Measurement-Period~~Deferred ~~Adjustments.~~Taxes,” ~~The~~ ~~amendments~~which inchanges ~~this~~how ~~ASU~~deferred ~~require~~taxes ~~that an acquirer recognize adjustments to provisional amounts that~~ are ~~identified~~classified ~~during~~on ~~the~~organizations’ ~~measurement~~balance ~~period in the reporting period in which the adjustment amounts are determined~~sheets. The ~~amendments in this~~ ASU ~~also~~eliminates ~~require that~~ the ~~acquirer~~current ~~record,~~requirement infor ~~the~~organizations ~~same~~to ~~period’s~~present ~~financial~~deferred ~~statements,~~tax ~~the~~liabilities ~~effect~~and onassets ~~earnings~~as ofcurrent ~~changes~~and noncurrent in ~~depreciation,~~a ~~amortization,~~classified orbalance ~~other~~sheet. ~~income effects~~Instead, iforganizations ~~any,~~will asbe arequired ~~result~~to ofclassify ~~the~~all ~~change~~deferred totax ~~the~~assets ~~provisional~~and ~~amounts,~~liabilities ~~calculated~~ as ~~if the accounting had been completed at the acquisition date~~noncurrent. ~~Additionally,~~The ~~the~~ amendments inapply ~~this ASU require an entity~~ to ~~present~~all ~~separately~~organizations ~~on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item~~ that ~~would~~present ~~have~~a ~~been~~classified ~~recorded~~balance ~~in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date~~sheet. The standard will be effective for ~~the~~financial ~~first~~statements ~~interim~~issued ~~period~~for ~~within~~ annual ~~reporting~~ periods beginning after December 15, ~~2015. Early adoption is permitted. The Company is evaluating this ASU~~2016, ~~however~~and weinterim doperiods ~~not~~within ~~anticipate~~those ~~that~~annual ~~the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures~~periods.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” This ASU amends existing guidance related to the recognition, measurement, presentation, and disclosure of financial instruments. The ASU eliminates the existing requirement to disclose the methods and significant assumptions used to estimate the fair value required to be disclosed for financial instruments measured at amortized cost on the balance sheet, instead requiring entities to disclose the fair value of these financial instruments using the exit price. This ASU also requires an entity that elects to measure a liability at fair value to present separately in other comprehensive income the portion of the total change in the liability’s fair value that is due to a change in credit risk specifically related to the financial instrument. Additionally, this ASU requires that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or in the notes to the financial statements. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017. Early adoption is only permitted for separate presentation in other comprehensive income as of the beginning of the fiscal year of adoption. The standard should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” The objective of this ASU is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and increasing disclosure requirements to include key information about leasing arrangements. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. When measuring assets and liabilities arising from a lease, a lessee should include payments to be made in optional periods, and optional payments to purchase, only if the lessee is reasonably certain to exercise the option. This new guidance continues to differentiate between finance leases and operating leases; there have been no significant changes in the recognition, measurement, and presentation of expenses and cash flows. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The standard must be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is evaluating this update.

In March 2016, the FASB issued ASU 2016-06, “Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments,” which applies to all entities that are issuers of or investors in debt instruments (or hybrid financial instruments that are determined to have a debt host) with embedded call (put) options. This amendment requires an entity to assess the embedded call (put) options solely in accordance with the four-step decision sequence. Additionally, this ASU clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, which is one of the criteria for bifurcating an embedded derivative. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted, including in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The standard should be applied on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).” When another party is involved in providing goods or services to a customer, this ASU provides additional guidance for entities in determining whether the nature of its promise is to provide that good or service to the customer (i.e. the entity is the principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is the agent). This amendment clarifies that an entity determine whether it is a principal or an agent for each specified good or service promised to a customer and determine the nature of each specified good or service. The effective date and transition for this ASU is the same as ASU 2014-09. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” The amendment in this ASU affects all organizations that issue share-based payment awards to employees and is intended to simplify several aspects of the accounting for these awards, including income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and allowing an accounting policy election to account for forfeitures as they occur. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted, however an entity must adopt all of the amendments in the same period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Transition guidance is dependent on the individual amendment within the update. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” This standard clarifies the guidance in ASU 2014-09 for entities in identifying performance obligations, and the licensing implementation guidance. The ASU clarifies that an entity is not required to assess whether promised goods or services are performance obligations if they are immaterial to the contract. This update also allows entities to make a policy election to account for shipping and handling occurring after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good rather than an additional promise. Additionally, the update includes clarification on whether an entity’s promise to grant a customer a license to intellectual property that has a significant standalone functionality or symbolic intellectual property, that does not have significant standalone functionality, include support during the license period. The effective date and transition for this ASU is the same as ASU 2014-09. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

(f) Other Significant Accounting Policies

For further information on our significant accounting policies, see Note 1 of the notes to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

NOTE 2. Acquisitions and Divestitures

Acquisitions

~~There~~Spiracur ~~were no significant acquisitions during the nine months ended September 30, 2015~~Inc.

10On December 1, 2015, we closed the acquisition of the SNaP business from Spiracur Inc., expanding our offering in disposable, portable, mechanical negative pressure wound therapy ("NPWT") technology, and allowing our sales and service channels to accelerate the expansion of the SNaP Therapy System to patients and their care teams around the world who need access to NPWT devices. The aggregate purchase price of this acquisition was $42.5 million, all of which was paid in cash. The allocation of the purchase price to the tangible and identifiable intangible assets was based on their estimated fair values as of the acquisition date using the income approach. The excess of the purchase price over the identifiable intangible and net tangible assets was allocated to goodwill, which is not deductible for tax purposes. Goodwill recognized was primarily attributable to potential operational synergies related to overhead cost reductions. The purchase price allocation is preliminary, pending the final determination of the fair value of certain assumed assets and liabilities. As these issues are identified, modified or resolved, resulting increases or decreases to the preliminary value of assets and liabilities are offset by a change to goodwill. Adjustments to these estimates will be included in the final allocation of the purchase price.

The consolidated financial statements include the results of operations from this business combination from the date of the acquisition. Had the transaction occurred at the beginning of fiscal 2015, consolidated results of operations would not have differed materially from reported results.

The following table represents the preliminary allocation of the purchase price ($ in thousands):



	December 31, 2015			Adjustments			March 31, 2016
Goodwill	$	27,525		$	652		$	28,177
Identifiable intangible assets:
Customer relationships	5,800						5,800
Developed technology	6,400						6,400
Tradenames	2,400						2,400
Tangible assets acquired and liabilities assumed:
Inventories	1,741						1,741
Other current assets	125						125
Property, plant and equipment	250						250
Current liabilities	(713		)	(1,639		)	(2,352		)
Other non-current liabilities	(987		)	987			—
Total purchase price	$	42,541		$	—		$	42,541

Purchase accounting rules require that as certain pre-acquisition issues are identified, modified or resolved, resulting increases or decreases to the preliminary value of assets and liabilities are offset by a change in goodwill. Modifications to goodwill reflected in the “Adjustments” column above were primarily the result of assumed liabilities.

Divestitures

~~SPY®~~There ~~Elite~~were ~~System~~no divestitures during the three months ended March 31, 2016.

On October 29, 2014, LifeCell Corporation entered into an agreement with Novadaq® Technologies Inc. (“Novadaq”) to transfer all marketing and distribution rights to the SPY® Elite System from LifeCell to Novadaq, effective November 30, 2014. 12

The operating results of the SPY® Elite System product portfolio included in discontinued operations are as follows (in thousands):

	Three months ended September 30,		Nine months ended September 30,
	2014		2014
Revenue	$	6,858	$	17,755
Earnings before income taxes	$	2,273	$	5,172
Income tax expense	$	875	$	1,991
Earnings from discontinued operations, net of tax	$	1,398	$	3,181

NOTE 3. Supplemental Balance Sheet Data

(a) Accounts Receivable, net

Accounts receivable consist of the following (in thousands):

	September 30, 2015			December 31, 2014
	March 31, 2016			December 31, 2015
Gross trade accounts receivable:
Billed trade accounts receivable	$	~~402~~440,~~363~~710		$	~~396~~429,~~329~~556
Unbilled receivables	4342,~~182~~032			3948,~~293~~795
Less: Allowance for revenue adjustments	(6662,~~031~~767		)	(6166,~~460~~868		)
Gross trade accounts receivable	~~379~~419,~~514~~975			~~374~~411,~~162~~483
Less: Allowance for bad debt	(12,~~036~~425		)	(1311,~~087~~372		)
Net trade accounts receivable	~~367~~407,~~478~~550			~~361~~400,~~075~~111
Other receivables	1512,~~960~~333			913,~~408~~420
	$	~~383~~419,~~438~~883		$	~~370~~413,~~483~~531

(b) Inventories, net

Inventories consist of the following (in thousands):

	September 30, 2015			December 31, 2014
	March 31, 2016			December 31, 2015
Finished goods and tissue available for distribution	$	~~131~~139,~~819~~589		$	~~127~~133,~~253~~293
Goods and tissue in-process	1013,~~390~~677			69,~~887~~778
Raw materials, supplies, parts and unprocessed tissue	6765,~~941~~767			67,~~567~~433
	210,150			201,707
	219,033			210,504
Less: Amounts expected to be converted into equipment for short-term rental	(910,~~625~~580		)	(79,~~515~~597		)
Reserve for excess and obsolete inventory	(1819,~~373~~653		)	(1519,~~970~~598		)
	$	~~182~~188,~~152~~800		$	~~178~~181,~~222~~309

1113

NOTE 4. Long-Term Debt

Long-term debt consists of the following (in thousands):

	September 30, 2015			December 31, 2014
	March 31, 2016			December 31, 2015
Senior Dollar Term E-1 Credit Facility – due 2018	$	1,~~912~~902,~~641~~907		$	1,~~927~~907,~~241~~774
Senior Euro Term E-1 Credit Facility – due 2018	~~268~~272,~~762~~784			~~293~~260,~~746~~946
Senior Term E-2 Credit Facility – due 2016	312,962			315,351
Senior Term E-2 Credit Facility – due 2016 (1)	—			312,166
10.5% Second Lien Senior Secured Notes due 2018	1,750,000			1,750,000
12.5% Senior Unsecured Notes due 2019	612,000			612,000
3.25% Convertible Senior Notes due 2015	—			101
7.875% First Lien Senior Secured Notes due 2021	400,000			—
Notional amount of debt	4,~~856~~937,~~365~~691			4,~~898~~842,~~439~~886
Senior Dollar Term E-1 Credit Facility Discount, net of accretion	(2218,~~892~~670		)	(2420,~~241~~792		)
Senior Euro Term E-1 Credit Facility Discount, net of accretion	(54,~~906~~919		)	(75,~~376~~224		)
Senior Term E-2 Credit Facility Discount, net of accretion	~~(2,284~~—		)	(21,~~955~~770		)
Second Lien Senior Secured Notes Discount, net of accretion	(1614,~~894~~533		)	(2015,~~205~~729		)
Senior Unsecured Notes Discount, net of accretion	(2,~~338~~113		)	(2,~~651~~227		)
Net discount on debt	(5040,~~314~~235		)	(5745,~~428~~742		)
Total debt, net of discount	4,806,051			4,841,011
Net debt issuance costs	(55,085		)	(54,651		)
Less: Current installments	(25,388		)	(25,721		)
Total debt, net of discount and debt issuance costs	4,842,371			4,742,493
	$	4,780,663		$	4,815,290
Less: Current installments	(22,258		)	(22,130		)
	$	4,820,113		$	4,720,363

(1) All amounts outstanding under the Senior ~~Secured~~Term E-2 Credit Facility were paid in full on February 9, 2016 with proceeds from the offering of the 7.875% First Lien Senior Secured Notes due 2021.

~~Our senior secured credit facility (the “~~Senior Secured Credit Facility”) includes a $200 million revolving credit facility (the “Revolving Credit Facility”). Amounts available under the Revolving Credit Facility are available for borrowing and reborrowing until maturity. At September 30, 2015 and December 31, 2014, no revolving credit loans were outstanding and we had outstanding letters of credit issued by banks which are party to the Senior Secured Credit Facility of $38.3 million and $39.0 million, respectively. In addition, we had $8.8 million and $11.4 million of letters of credit issued by a bank not party to the Senior Secured Credit Facility as of September 30, 2015 and December 31, 2014, respectively. The capacity of the Revolving Credit Facility is reduced for the $38.3 million and $39.0 million of letters of credit issued by banks which are party to the Senior Secured Credit Facility as of September 30, 2015 and December 31, 2014, respectively. The resulting availability under the Revolving Credit Facility was $161.7 million and $161.0 million at September 30, 2015 and December 31, 2014, respectively. Commitment fees accrue at a rate of 0.50% on the amounts available under the Revolving Credit Facility.Facilities

~~Interest. On~~Our ~~March~~senior ~~10,~~secured ~~2015,~~credit wefacilities ~~entered~~(the ~~into~~“Senior ~~Amendment~~Secured ~~No.~~Credit 6Facilities”) toincludes ~~our~~a ~~Senior~~$200 ~~Secured~~million ~~Credit~~revolving ~~Facility~~credit facility (the “~~Amendment~~Revolving ~~No.~~Credit 6Facility”). In ~~connection~~Amounts ~~with~~available ~~Amendment~~under Nothe Revolving Credit Facility are available for borrowing and reborrowing until maturity. 6At March 31, ~~certain~~2016 ~~applicable~~and ~~rates~~December 31, 2015, no revolving credit loans were ~~modified~~outstanding soand ~~that~~we ~~(i)~~had ~~Dollar~~outstanding ~~Term~~letters ~~E-1~~of ~~Loans~~credit ~~bear~~issued ~~interest~~by atbanks awhich ~~rate~~are ~~equal~~party to, atthe ~~KCI’s~~Senior ~~election,~~Secured aCredit ~~Eurocurrency~~Facilities ~~rate~~of ~~plus~~$37.9 3million and $38.~~50%~~2 ormillion, anrespectively. ~~adjusted~~In ~~base~~addition, ~~rate~~we ~~plus~~had 2$7.~~50%,~~7 ~~(ii)~~million ~~Euro~~and ~~Term~~$8.5 ~~E-1~~million ~~Loans~~of ~~bear~~letters ~~interest~~of atcredit issued by a ~~rate~~bank ~~equal~~not party to, atthe ~~KCI’s~~Senior ~~election~~Secured Credit Facilities as of March 31, a2016 ~~Eurocurrency~~and ~~rate~~December 31, ~~plus~~2015, 3respectively.~~75%~~ orThe ancapacity ~~adjusted~~of ~~base~~the ~~rate~~Revolving ~~plus~~Credit 2Facility is reduced for the $37.~~75%,~~9 million and ~~(iii)~~$38.2 ~~Term~~million ~~E-2~~of ~~Loans~~letters ~~bear~~of ~~interest~~credit atissued aby ~~rate~~banks ~~equal~~which ~~to,~~are atparty ~~KCI’s~~to ~~election,~~the aSenior ~~Eurocurrency~~Secured ~~rate~~Credit ~~plus~~Facilities ~~3.00%~~as orof anMarch 31, ~~adjusted~~2016 ~~base~~and ~~rate~~December 31, ~~plus~~2015, 2respectively.~~00%.~~ The ~~Eurocurrency~~resulting ~~rate~~availability ~~shall~~under bethe ~~subject~~Revolving toCredit aFacility ~~floor~~was of $162.1 million and $161.~~00%~~8 million at March 31, 2016 and ~~the~~December 31, ~~adjusted~~2015, ~~base~~respectively. ~~rate~~Commitment ~~shall~~fees beaccrue ~~subject~~at to a ~~floor~~rate of 20.0050% on the amounts available under the Revolving Credit Facility.

On February 9, 2016, we entered into Amendment No. 7 to the Senior Secured Credit Facilities. Pursuant to Amendment No. 7, among other things, the maturity date of certain consenting lenders’ commitments under the Revolving Credit Facility was extended to November 4, 2017. Promptly after the effectiveness of Amendment No. 7, we permanently reduced, or the Permanent Reduction, a portion of the commitments under our Revolving Credit Facility of lenders that did not consent to extend the maturity date of their commitments under the Revolving Credit Facility pursuant to Amendment No. 7. On February 9, 2016, we also entered into Amendment No. 8 to the Senior Secured Credit Facilities. In connection with Amendment No. 8, certain lenders agreed to provide incremental commitments under the Revolving Credit Facility in a principal amount equal to the principal amount of the commitments subject to the Permanent Reduction, and such incremental commitments also have a maturity date of November 4, 2017. After giving effect to Amendment No. 7 and Amendment No. 8, we have aggregate revolving loan commitments under our Revolving Credit Facility of $171.3 million maturing on November 4, 2017, with an additional $28.7 million in revolving loan commitments continuing to mature on November 4, 2016.

7.875% First Lien Senior Secured Notes

On February 9, 2016, Kinetic Concepts, Inc. and KCI USA, Inc., each a wholly-owned subsidiary of Acelity L.P. Inc. (together, the "First Lien Notes Issuers") issued $400.0 million aggregate principal amount of 7.875% First Lien Senior Secured notes due 2021 (the "First Lien Notes").

Interest. Interest on the First Lien Notes accrues at the rate of 7.875% per annum and is payable semiannually in arrears on each February 15 and August 15, beginning on August 15, 2016. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months.

Collateral. The First Lien Notes are secured on a first priority basis by a perfected security interest in substantially all of the First Lien Notes Issuers' and the guarantors' tangible and intangible assets (subject to certain exceptions), including U.S. registered intellectual property and all of the capital stock of each of Acelity L.P. Inc.'s direct and indirect wholly-owned material restricted subsidiaries, including the First Lien Notes Issuers (limited, in the case of foreign subsidiaries and domestic foreign holding companies, to 65% of the voting capital stock of material foreign subsidiaries and domestic foreign holding companies). The liens securing the first lien notes are subject to permitted liens.

Guarantors. Our obligations under the First Lien Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by Acelity L.P. Inc., Chiron Topco, Inc., Chiron Holdings, Inc., LifeCell Corporation and each of Acelity L.P. Inc.’s other subsidiaries to the extent such entities guarantee indebtedness under the Senior Secured Credit Facilities or the 10.5% Second Lien Senior Secured Notes due 2018 (the "Second Lien Notes") and the 12.5% Senior Unsecured Notes due 2019 (together with the Second Lien Notes, the "Existing Notes").

Maturity. The First Lien Notes will mature on February 15, 2021.

Covenants. The indenture governing the First Lien Notes contains covenants customary for similar transactions, including limitations or restrictions on our ability to:


•	incur additional indebtedness and guarantee indebtedness;


•	pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;


•	prepay, redeem or repurchase certain debt;


•	make loans and investments;


•	sell or otherwise dispose of assets;


•	incur liens;


•	enter into transactions with affiliates;


•	enter into agreements restricting our subsidiaries’ ability to pay dividends; and


•	consolidate, merge or sell all or substantially all of our assets.

Optional Redemption. At any time prior to February 15, 2018, the First Lien Notes Issuers, at their option, may redeem up to 40% of the aggregate principal amount of the First Lien Notes with the net cash proceeds of certain equity offerings, at a redemption price equal to 107.875% of the aggregate principal amount of the First Lien Notes being redeemed plus accrued and unpaid interest, if any.

At any time prior to February 15, 2018, the First Lien Notes Issuers, at their option, may redeem all or part of the First Lien Notes at a redemption price equal to 100% of the aggregate principal amount of the First Lien Notes to be redeemed, plus a make-whole premium plus accrued and unpaid interest, if any, to the date of redemption.

At any time on or after February 15, 2018, the First Lien Notes Issuers may redeem the First Lien Notes, in whole or in part, at the following redemption prices (expressed as percentages of the principal amount) if redeemed during the twelve‑month period commencing on February 15 of the year set forth below, plus, in each case, accrued and unpaid interest thereon, if any, to the date of redemption:



Year		Price
2018		103.938%
2019		101.969%
2020 and thereafter		100.000%

Change of Control. If First Lien Notes Issuers experience certain kinds of changes of control specified in the indenture governing the First Lien Notes, the First Lien Notes Issuers will be required to offer to repurchase the First Lien Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any.

Events of Default. The indenture governing the First Lien Notes contains events of default (subject in certain cases to customary grace and cure periods) including, but not limited to, failure to pay principal or interest, breach of covenants, payment defaults or acceleration of other indebtedness, a bankruptcy or similar proceeding being instituted by or against us, rendering of certain monetary judgments against us, and impairments of loan documentation or security.

Registration. The First Lien Notes and related guarantees have not been and will not be registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction.

Covenants

As ~~a result~~ of ~~Amendment~~March 31, ~~No. 6~~2016, ~~the~~we ~~financial covenants~~ were ~~amended~~in tocompliance ~~remove~~with the ~~interest~~covenants ~~coverage~~under ~~ratio in its entirety and to set~~ the ~~total~~credit ~~leverage~~agreement ~~ratio~~governing ~~for~~our ~~any~~Senior ~~test~~Secured ~~period~~Credit toFacilities beand noindentures ~~greater~~governing ~~than 8.25:1.00. In addition, certain other covenants were amended, including with respect to~~ the ~~incurrence~~First ofLien ~~incremental~~Notes ~~facilities~~ and ~~asset~~the ~~sales.~~Existing ~~As of September 30, 2015, we were in compliance with all covenants under our credit agreement and indentures~~Notes.

For further information on our long-term debt, see Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

NOTE 5. Derivative Financial Instruments and Fair Value Measurements

We are exposed to credit loss in the event of nonperformance by counterparties to the extent of the fair values of the outstanding interest rate swap agreements, interest rate cap agreements and foreign currency exchange contracts, but we do not anticipate nonperformance by any of the counterparties. All derivative instruments are recorded on the balance sheets at fair value. We do not use financial instruments for speculative or trading purposes.

Interest Rate Protection

At ~~September~~March 3031, ~~2015~~2016 and December 31, ~~2014~~2015, we were party to three interest rate swap agreements which are used to convert a portion of our outstanding variable rate debt to a fixed rate basis. These agreements have not been designated as hedging instruments, and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period. The interest rate swap agreements have receive rates based on the higher of three-month USD LIBOR or 1.25% and pay rates based on fixed rates. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $1.7 million to $561.48 million until maturity.

The following table summarizes our interest rate swap agreements (dollars in thousands):

Effective Dates	Outstanding Notional Amount	Fixed Interest Rate
12/31/13-12/31/16	$~~478~~459,~~700~~333	2.256%
12/31/13-12/31/16	$~~478~~459,~~700~~333	2.249%
12/31/13-12/31/16	$~~478~~459,~~700~~333	2.250%

hedge instruments. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $4.4 million to $84.5 million until maturity.

Foreign Currency Exchange Rate Mitigation

At ~~September~~March 3031, ~~2015~~2016 and December 31, ~~2014~~2015, we had no outstanding foreign currency exchange contracts.

Fair Value Measurements

The Codification defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. The Fair Value Measurements and Disclosure topic of the Codification establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and long-term obligations, excluding our borrowings under our Senior Secured Credit ~~Facility~~Facilities and fixed rate long-term debt, approximates fair value. The fair value of our borrowings under our Senior Secured Credit ~~Facility~~Facilities and fixed rate long-term debt ~~as determined using Level 2 inputs~~ was $2.~~489~~164 billion and $2.~~479~~700 billion, respectively, at ~~September~~March 3031, ~~2015~~2016. The fair value of our borrowings under our Senior Secured Credit ~~Facility~~Facilities and fixed rate long-term debt was $2.~~501~~400 billion and $2.~~584~~257 billion, respectively, at December 31, ~~2014~~2015. The fair value of our long-term debt was estimated based upon open-market trades at or near ~~period~~year end.

All of our derivatives, as of the reporting date, use inputs considered as Level 2. The interest rate swap agreements are valued using a discounted cash flow model that takes into account the present value of the expected future cash flows under the terms of the agreements by using market information available as of the reporting date, including prevailing interest rates and related forward interest rate curves.

The following table sets forth the location and aggregate fair value amounts of all derivative instruments with credit-related contingent features (in thousands):

Asset Derivatives

Liability Derivatives

BalanceSheetLocation

Fair Value

BalanceSheetLocation

Fair Value

September 30, 2015

December 31, 2014

September 30, 2015

December 31, 2014

March 31, 2016

December 31, 2015

March 31, 2016

December 31, 2015

Derivatives not designated as hedging instruments

Interest rate swap agreements

Prepaid expenses and other

—

Accrued expenses and other

139,~~076~~431

1312,~~936~~243

Interest rate swap agreements

Other non-current assets

—

Other non-current liabilities

~~2,950~~—

~~8,067~~—

Total derivatives

—

169,~~026~~431

2212,~~003~~243

The following table summarizes the amount of gain (loss) on derivatives not designated as hedging instruments (dollars in thousands):

	Three months ended September 30,						Nine months ended September 30,
	Three months ended March 31,
	2015			2014			2015			2014
	2016			2015
Interest rate swap agreements	$	(~~869~~682	)	$	1(3,~~630~~348	)	$	~~(5,136~~	)	$	~~(2,732~~	)
Foreign currency exchange contracts	—			—			—			62
	$	(~~869~~682	)	$	1(3,~~630~~348	)	$	~~(5,136~~	)	$	~~(2,670~~	)

Certain of our derivative instruments contain provisions that require compliance with the restrictive covenants of our Senior Secured Credit ~~Facility~~Facilities. For further information regarding the restrictive covenants of credit facilities, see Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

If we default under our credit facilities, the lenders could require immediate repayment of the entire outstanding principal balance. If those lenders require immediate repayment, we may not be able to repay them which could result in the foreclosure of substantially all of our assets. In these circumstances, the counterparties to the derivative instruments could request immediate payment or full collateralization on derivative instruments in net liability positions. Certain of our derivative counterparties are also parties to our Senior Secured Credit Facility.17

NoIf ~~collateral~~we ~~has~~default ~~been~~under ~~posted~~our bycredit usfacilities, in the ~~normal~~lenders ~~course~~could ofrequire ~~business. If~~immediate ~~the~~repayment ~~credit-related~~of ~~contingent~~the ~~features~~entire ~~underlying~~outstanding ~~these~~principal ~~agreements~~balance. If ~~were~~those ~~triggered~~lenders onrequire ~~September 30,~~immediate ~~2015~~repayment, we ~~could~~may not be ~~required~~able to ~~settle~~repay orthem ~~post~~which could result in the ~~full~~foreclosure ~~amount~~of assubstantially ~~collateral~~all of our assets. In these circumstances, the counterparties to the ~~respective~~derivative ~~agreement~~instruments could request immediate payment or full collateralization on derivative instruments in net liability positions. Certain of our derivative counterparties are also parties to our Senior Secured Credit Facilities.

WeNo ~~did~~collateral ~~not~~has ~~have~~been ~~any~~posted ~~measurements~~by ofus ~~financial~~in ~~assets~~the ornormal ~~financial~~course ~~liabilities~~of atbusiness. If ~~fair~~the ~~value~~credit-related oncontingent afeatures ~~nonrecurring~~underlying ~~basis~~these atagreements ~~September 30,~~were ~~2015~~triggered oron ~~December~~March 31, ~~2014~~2016, we could be required to settle or post the full amount as collateral to the respective agreement counterparties.

We did not have any measurements of financial assets or financial liabilities at fair value on a nonrecurring basis at March 31, 2016 or December 31, 2015.

NOTE 6. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	AccumulatedForeignCurrencyTranslationAdjustment			AccumulatedOtherComprehensiveIncome (Loss)
Balances at December 31, 2014	$	(10,074	)	$	(10,074	)
Balances at December 31, 2015	$	(19,734	)	$	(19,734	)
Foreign currency translation adjustment, net of taxes of $478	(7,933		)	(7,933		)
Foreign currency translation adjustment, net of tax benefit of $755	4,098			4,098
Balances at September 30, 2015	$	(18,007	)	$	(18,007	)
Balances at March 31, 2016	$	(15,636	)	$	(15,636	)

During the ~~nine~~three months ended ~~September~~March 3031, ~~2015~~2016, there were no reclassification adjustments out of accumulated other comprehensive loss to net loss.

NOTE 7. Commitments and Contingencies

Legal Proceedings

Intellectual Property Litigation

As the owner and exclusive licensee of patents, from time to time, we are a party to proceedings challenging these patents, including challenges in U.S. federal courts, foreign courts, foreign patent offices and the U.S. Patent and Trademark Office. Additionally, from time to time, we are a party to litigation we initiate against others we contend infringe these patents, which often results in counterclaims regarding the validity of such patents. At other times, we are party to litigation initiated by others who contend we infringe their patents. It is not possible to reliably predict the outcome of the proceedings described below. However, if we are unable to effectively enforce our intellectual property rights, third parties may become more aggressive in the marketing of competitive products around the world.

In September 2013, LifeNet Health ("LifeNet") filed suit against LifeCell Corporation ("LifeCell") in the U.S. District Court for the Eastern District of Virginia, Norfolk Division. LifeNet ~~alleges~~alleged that two LifeCell products, Strattice and AlloDerm Ready to Use, infringe LifeNet’s U.S. Patent No. 6,569,200, (or the ~~" '~~‘200 Patent"). In On November 18, 2014, a jury found that the ‘200 Patent was not invalid and was infringed and further awarded LifeNet a lump sum damages amount of $34.7 million. As a result of this decision, we recorded a liability of $34.7 million in the fourth quarter of 2014. We disagree with the result at this stage in the litigation and believe that LifeCell’s defenses to the claims are meritorious. LifeCell will continue to vigorously assert its defenses during the appeal stages of this litigation and intends to defend any further claims by LifeNet. LifeCell has filed an appeal in the U.S. Federal Circuit Court of Appeals in Washington D.C. on multiple grounds. The hearing before the Federal Circuit Court of Appeals was held in March 2016. In September 2015, LifeCell filed suit against LifeNet in the U.S. District Court for the District of New Jersey seeking declaratory judgment that LifeCell’s products do not infringe U.S. Patent No. 9,125,971, (or the ~~" '~~‘971 Patent"), which was issued to LifeNet the same day. In February 2016, a magistrate judge ordered the case transferred to Virginia, which LifeCell is appealing. LifeCell also filed a petition with United States Patent and Trademark Office to invalidate the ‘971 Patent. The ‘971 Patent is a continuation of the ‘200 Patent.

Products Liability Litigation

LifeCell is a defendant in approximately ~~354~~355 lawsuits filed by individuals alleging personal injury and seeking monetary damages for failed hernia repair procedures using LifeCell’s AlloDerm products. These cases have been consolidated for case management purposes in Middlesex County, New Jersey. The trial court has issued a pre-trial order incorporating the bellwether practice of trying the claims of some plaintiffs to determine the likelihood of settlement or to avoid relitigating common issues in every case. Discovery was completed in four bellwether cases. In August 2015, LifeCell was successful in obtaining a summary judgment resulting in the dismissal of two of the four bellwether cases, and the dismissal of the design defect claims in the remaining two bellwether cases. The plaintiffs have appealed these decisions. Trial of the first remaining bellwether case ishas ~~currently~~been ~~scheduled~~postponed ~~for~~and ~~January~~has ~~2016~~not yet been rescheduled. Although it is not possible to reliably predict the outcome of the litigation, we believe that our defenses to these claims are meritorious and we will defend against these suits vigorously. Based on our existing insurance coverage and our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. Because discovery of damages has been limited to the four bellwether cases, we do not know the damages allegedly suffered by the remaining plaintiffs. As such, it is impossible to predict or estimate potential losses if our defenses to these cases are unsuccessful.

LifeCell has been named as a defendant in approximately ~~257~~ 258 lawsuits in state and U.S. federal courts alleging personal injury and seeking monetary damages for failed gynecological procedures using a human tissue product processed by LifeCell and sold by one of LifeCell’s distributors, Boston Scientific, under the name Repliform. There are approximately 254 ~~253~~ LifeCell cases filed in two consolidated dockets in Middlesex County, Massachusetts. The cases are in the initial phase and no discovery has occurred. Two cases are pending in a multi-district U.S. federal case in West Virginia that is proceeding very slowly. LifeCell has been named, but not served, in 12 cases with multiple plaintiffs and defendants in St. Louis, Missouri State court. The St. Louis cases are aimed at the entire pelvic mesh industry and it is unknown at this time if Repliform was actually implanted in any of the plaintiffs. The two remaining cases are in Delaware and Minnesota. Based on our existing insurance coverage and our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. As these cases are in their early stages it is not possible to predict or estimate potential losses if our defenses to these cases are unsuccessful.

Other Litigation

In 2009, KCI received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General, (“or OIG”), seeking records regarding our billing practices under the local coverage policies of the four regional Durable Medical Equipment Medicare Administrative Contractors, (“or DME MACs”). KCI cooperated with the OIG'’s inquiry and provided substantial documentation to the OIG and the U.S. Attorneys'’ office in response to its request. The government'’s inquiry stemmed from the filing under seal of two 2008 qui tam actions against KCI by two former employees in the U.S. District Court, Central District of California, Western Division. These cases are captioned United States of America, ex rel. Steven J. Hartpence v. Kinetic Concepts, Inc. et al, and United States of America, ex rel. Geraldine Godecke v. Kinetic Concepts, Inc., et al. The complaints contend that KCI violated the federal False Claims Act by billing in a manner that was not consistent with the Local Coverage Determinations issued by the DME MACs and seek recovery of monetary damages. Following the completion of the government'’s review and its decision declining to intervene in such suits, the live pleadings were ordered unsealed in 2011. After reviewing the allegations, KCI filed motions seeking the dismissal of the suits on multiple grounds. In 2012, the District Court granted KCI'’s motions dismissing all of the claims under the False Claims Act. The cases ~~went~~were appealed to ~~appeal in~~ the U.S. Court of Appeals for the Ninth Circuit which reversed the District Court'’s dismissal of the suits and remanded the cases back to the District Court for further proceedings. We believe that our defenses to the claims in the Hartpence and ~~Goedecke~~Godecke cases are meritorious and that we have no liability under the False Claims Act for their allegations. However, it is not possible to predict the outcome of this litigation nor is it possible to estimate any damages that may be awarded if we are unsuccessful in the litigation.

We are a party to several additional lawsuits arising in the ordinary course of our business. Additionally, the manufacturing and marketing of medical products necessarily entails an inherent risk of product liability claims. We maintain multiple layers of product liability insurance coverage and we believe these policies and the amounts of coverage are appropriate and adequate.

Other Commitments and Contingencies

As a healthcare supplier, we are subject to extensive government regulation, including laws and regulations directed at ascertaining the appropriateness of reimbursement, preventing fraud and abuse and otherwise regulating reimbursement under various government programs. The marketing, billing, documenting and other practices are all subject to government oversight and review. To ensure compliance with Medicare and other regulations, regional carriers often conduct audits and request patient records and other documents to support claims submitted by us for payment of services rendered to customers.

We also are subject to routine pre-payment and post-payment audits of durable medical equipment (“DME”) claims submitted to Medicare Part B. These audits typically involve a complex medical review, by Medicare or its designated contractors and representatives, of documentation supporting the therapy provided by us. While Medicare requires us to obtain a comprehensive physician order prior to providing products and services, we are not required to obtain the written medical record in advance of therapy as long as the underlying medical records reported to us support the coverage criteria and medical necessity information included in such claim. Following a Medicare request for supporting documentation, we are obligated to procure and submit the underlying medical records retained by various clinical providers, medical facilities and prescribers. Obtaining these medical records in connection with a claims audit may be challenging and, in any event, all of these records are subject to further examination, interpretation and dispute by an auditing authority. Under standard Medicare procedures, we are entitled to demonstrate the sufficiency of documentation and the establishment of medical necessity, and we have the right to appeal any adverse determinations. If a determination is made that our records or the patients’ medical records are insufficient to meet medical necessity or Medicare reimbursement requirements for the claims, we could be subject to denial or overpayment demands for claims submitted for Medicare reimbursement. In the rare event that an audit results in major discrepancies of claims records which lacked proof of medical necessity, Medicare may be entitled to take additional corrective measures, including: extrapolation of the results of the audit across a wider population of claims, submitting recoupment demands for claims other than those examined in the audit, or placing the organization on a full prepayment review. These audits have increased over the last two years from being negligible to approximately 10% of our claims. While eventually receiving payment on a high percent of the claims subject to these audits, payment timeliness may range from a few months up to a year resulting in increasing Medicare accounts receivable balances.19

16 We also are subject to routine pre-payment and post-payment audits of durable medical equipment (“DME”) claims submitted to Medicare. These audits typically involve a complex medical review, by Medicare or its designated contractors and representatives, of documentation supporting the therapy provided by us. While Medicare requires us to obtain a comprehensive physician order prior to providing products and services, we are not required to obtain the written medical record in advance of therapy as long as the underlying medical records reported to us support the coverage criteria and medical necessity information included in such claim. Following a Medicare request for supporting documentation, we are obligated to procure and submit the underlying medical records retained by various clinical providers, medical facilities and prescribers. Obtaining these medical records in connection with a claims audit may be challenging and, in any event, all of these records are subject to further examination, interpretation and dispute by an auditing authority. Under standard Medicare procedures, we are entitled to demonstrate the sufficiency of documentation and the establishment of medical necessity, and we have the right to appeal any adverse determinations. If a determination is made that our records or the patients’ medical records are insufficient to meet medical necessity or Medicare reimbursement requirements for the claims, we could be subject to denial or overpayment demands for claims submitted for Medicare reimbursement. In the rare event that an audit results in major discrepancies of claims records which lacked proof of medical necessity, Medicare may be entitled to take additional corrective measures, including: extrapolation of the results of the audit across a wider population of claims, submitting recoupment demands for claims other than those examined in the audit, or placing the organization on a full prepayment review. Over the twelve month period ended March 31, 2016, these audits have averaged approximately 12% of our claims. While eventually receiving payment on a high percent of the claims subject to these audits, payment timeliness may range from a few months up to a year resulting in increasing Medicare accounts receivable balances.

On June 30, 2014, KCI entered into a settlement agreement with Wake Forest University Health Sciences to fully and finally resolve the historical patent and royalty disputes between them relating to negative pressure wound therapy. As of March 31, 2016, the accompanying consolidated balance sheet included $83.8 million under the caption “accrued expenses and other” and $28.0 million under the caption “other non-current liabilities” representing the net present value of remaining payments under the settlement agreement discounted using our incremental borrowing rate as the discount rate.

NOTE 8. Segment Information

The Company is engaged in the rental and sale of advanced wound therapeutics and regenerative medicine products in ~~over~~approximately 7580 countries worldwide through direct sales and indirect operations. We have two reportable operating segments which correspond to our two businesses: Advanced Wound Therapeutics ("AWT") and Regenerative Medicine. Our ~~Advanced~~AWT ~~Wound Therapeutics~~ business is conducted by KCI and its subsidiaries, including Systagenix, while our Regenerative Medicine business is conducted by LifeCell and its subsidiaries. In most countries where we operate, certain aspects of our two businesses are supported by the same administrative staff, systems and infrastructure and, as such, we have allocated these costs between the businesses based on allocation methods including headcount, revenue and other methods as deemed appropriate. We measure segment profit (loss) as operating earnings (loss), which is defined as income (loss) before interest and other income, interest expense, foreign currency gains and losses, derivative instruments gains and losses and income taxes. All intercompany transactions are eliminated in computing revenue and operating earnings (loss).

Information on segments and a reconciliation of consolidated totals are as follows (in thousands):

	Three months ended September 30,						Nine months ended September 30,
	Three months ended March 31,
	2015			2014			2015			2014
	2016			2015
Revenue:
Advanced Wound Therapeutics	$	~~365~~339,~~819~~042		$	~~372~~337,~~965~~259		$	~~1,057,292~~		$	~~1,051,233~~
Regenerative Medicine	109,~~332~~874			104,~~611~~169			~~317,030~~			~~318,791~~
Other operations (1)	2,~~529~~450			42,~~217~~622			~~9,053~~			~~13,582~~
Total revenue	$	~~477~~451,~~680~~366		$	~~481~~444,~~793~~050		$	~~1,383,375~~		$	~~1,383,606~~
Operating earnings (loss):
Operating earnings:
Advanced Wound Therapeutics	$	~~126~~99,~~330~~664		$	~~131~~112,~~792~~885		$	~~356,857~~		$	~~324,160~~
Regenerative Medicine	3839,~~922~~275			3134,~~980~~019			~~108,287~~			~~93,853~~
Other operations (1)	~~421~~551			~~557~~447			~~1,410~~			~~1,858~~
Non-allocated costs:
General headquarter expense	(1,179		)	(1,063		)	(4,128		)	(3,475		)
General headquarter expense (2)	(1,568		)	(1,423		)
Equity-based compensation	(~~1,061~~768		)	(~~863~~535		)	~~(2,366~~		)	~~(2,966~~		)
Business optimization and transaction-related expenses (2)	(13,534		)	(26,138		)	(45,262		)	(88,462		)
Business optimization and transaction-related expenses (3)	(17,685		)	(15,376		)
Acquired intangible asset amortization (3)	(43,845		)	(47,918		)	(134,434		)	(147,361		)
Acquired intangible asset amortization (4)	(42,201		)	(45,877		)
Wake Forest settlement	—			—			—			(198,578		)
Total non-allocated costs	(62,222		)	(63,211		)
Total non-allocated costs	(59,619		)	(75,982		)	(186,190		)	(440,842		)
Total operating earnings	$	77,268		$	84,140
Total operating earnings (loss)	$	106,054		$	88,347		$	280,364		$	(20,971	)


(1)	Represents contract manufacturing operations conducted at our manufacturing facility in Gargrave, England.

(2) Represents general headquarter expenses ~~associated~~not ~~with~~allocated ~~our~~to ~~business~~the ~~optimization~~individual ~~initiatives~~segments, asincluding ~~well~~depreciation asassociated ~~management~~with ~~fees~~our ~~and~~purchase ~~costs~~accounting ~~associated~~fixed ~~with~~asset ~~acquisition,~~step ~~disposition~~up ~~and~~to ~~financing~~fair ~~activities~~value.

(3) Represents ~~amortization~~restructuring-related ofexpenses ~~acquired~~associated ~~intangible~~with ~~assets~~our ~~related~~business tooptimization ~~our~~initiatives ~~Merger~~as inwell ~~November~~as ~~2011,~~management ~~our~~fees ~~acquisition~~and ofcosts ~~Systagenix~~associated inwith ~~October~~acquisition, ~~2013~~disposition and ~~other~~financing ~~technology acquisitions~~activities.

17(4) Represents amortization of acquired intangible assets related to our 2011 LBO, our acquisition of Systagenix in October 2013 and other technology acquisitions.

NOTE 9. Guarantor Condensed Consolidating Financial Statements

Our ~~10.5%~~First ~~Second~~ Lien Notes and ~~12.5%~~Existing ~~Unsecured~~ Notes are fully and unconditionally guaranteed, jointly and severally, by us and each of our material 100% owned subsidiaries, other than the subsidiaries that are co-issuers of the notes, foreign subsidiaries and subsidiaries whose only assets are investments in foreign subsidiaries. The non-guarantor subsidiaries do not have any payment obligations under the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes. Subject to the terms of ~~the10.5%~~the ~~Second~~First Lien Notes and ~~12.5%~~Existing ~~Unsecured~~ Notes indentures, the guarantee of a subsidiary guarantor will terminate upon:

(1) a sale or other disposition (including by way of consolidation or merger) of the capital stock of such guarantor or the sale or disposition of all or substantially all the assets of such subsidiary guarantor (other than to the Company or a restricted subsidiary) otherwise permitted by the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes indentures,

(2) the designation in accordance with the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes indenture of the guarantor as an unrestricted subsidiary or the occurrence of any event after which the guarantor is no longer a restricted subsidiary,

(3) defeasance or discharge of the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes, or

(4) ~~upon~~ the achievement of investment grade status by the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes; provided that such guarantee shall be reinstated upon the reversion date.

In the event of a bankruptcy, liquidation or reorganization of any non-guarantor subsidiary, such non-guarantor subsidiary will pay the holders of its debt and other liabilities, including its trade creditors, before it will be able to distribute any of its assets to us. In the future, any non-U.S. subsidiaries, immaterial subsidiaries and subsidiaries that we designate as unrestricted subsidiaries under the ~~10.5%~~First ~~Second~~ Lien Notes and ~~12.5%~~Existing ~~Unsecured~~ Notes indentures will not guarantee the ~~10.5%~~First ~~Second~~ Lien Notes or ~~12.5%~~Existing ~~Unsecured~~ Notes. As of ~~September~~March 3031, ~~2015~~2016, there were no restrictions on the ability of subsidiary guarantors to transfer funds to the parent company.

As a result of the guarantee arrangements, we are presenting the following condensed consolidated balance sheets, statements of operations and comprehensive income (loss), and statements of cash flows of the issuer, the guarantor subsidiaries and the non-guarantor subsidiaries.

1822

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Balance Sheet

~~September~~March 3031, ~~2015~~2016

(in thousands)

(unaudited)

	Acelity L.P. Inc. Parent Company		Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Consolidated
Assets:
Current assets:
Cash and cash equivalents	$	398	$	2466,~~095~~900		$	37,~~379~~458	$	~~169~~148,~~138~~860	$	—		$	~~197~~223,~~010~~616
Accounts receivable, net	—		~~187~~199,~~029~~611			5361,~~341~~760		~~143~~158,~~068~~512		—			~~383~~419,~~438~~883
Inventories, net	—		8688,~~136~~390			~~103~~115,~~584~~886		~~105~~112,~~838~~654		(~~113~~128,~~406~~130		)	~~182~~188,~~152~~800
Deferred income taxes	—		1949,~~319~~794			78,~~434~~286		~~946~~—		—(14,299		)	2743,~~699~~781
Prepaid expenses and other	—		1612,~~628~~504			143,~~629~~771		~~243~~244,~~502~~835		(231,~~638~~246		)	4329,~~121~~864
Intercompany receivables	166		2,~~060~~128,~~253~~300			2,~~655~~871,~~517~~122		3171,~~384~~087		(45,~~747~~070,~~320~~675		)	—
Total current assets	564		2,~~393~~545,~~460~~499			23,~~837~~068,~~884~~283		~~693~~735,~~876~~948		(5,~~092~~444,~~364~~350		)	~~833~~905,~~420~~944
Net property, plant and equipment	—		~~302~~297,~~230~~632			6359,~~003~~575		~~130~~119,~~263~~019		(~~225~~210,~~419~~218		)	~~270~~266,~~077~~008
Debt issuance costs, net	—		59,998			—		—		—			59,998
Deferred income taxes	—		—			—		24,262		—			24,262
Deferred income taxes	—		—			—		26,705		—			26,705
Goodwill	—		2,511,417			732,138		162,920		—			3,406,475
Goodwill	—		2,483,240			732,138		162,920		—			3,378,298
Identifiable intangible assets, net	—		239,052			1,686,938		252,874		—			2,178,864
Identifiable intangible assets, net	—		259,638			1,735,640		275,046		—			2,270,324
Other non-current assets	—		1,115			282		3,250		—			4,647
Other non-current assets	—		1,231			270		94,171		(90,900		)	4,772
Intercompany loan receivables	—		735,000			439,937		—		(1,174,937		)	—
Intercompany loan receivables	—		745,000			433,281		—		(1,178,281		)	—
Intercompany investments	592,430		428,232			—		—		(1,020,662		)	—
Intercompany investments	629,849		462,677			161,170		—		(1,253,696		)	—
	$	592,994	$	6,757,947		$	5,987,153	$	1,298,273	$	(7,850,167	)	$	6,786,200
	$	630,413	$	6,707,474		$	5,963,386	$	1,382,981	$	(7,840,660	)	$	6,843,594
Liabilities and Equity:
Current liabilities:
Accounts payable	$	—	$	1715,~~255~~452		$	1113,~~946~~680	$	2123,~~919~~534	$	—		$	5152,~~120~~666
Accrued expenses and other	—		~~295~~287,~~281~~448			~~224~~253,~~659~~676		7366,~~979~~391		(~~188~~187,~~288~~311		)	~~405~~420,~~631~~204
Intercompany payables	910,~~553~~332		1,~~553~~801,~~950~~863			2,~~668~~745,~~943~~691		~~514~~512,~~874~~789		(45,~~747~~070,~~320~~675		)	—
Current installments of long-term debt	—		2522,~~388~~258			—		—		—			2522,~~388~~258
Income taxes payable	—		—			—5,159		34,284		—(606		)	38,837
Deferred income taxes	—		—			44113,~~928~~595		—14,299		—(14,299		)	44113,~~928~~595
Total current liabilities	910,~~553~~332		12,~~891~~127,~~874~~021			23,~~950~~131,~~476~~801		~~610~~621,~~775~~297		(45,~~935~~272,~~608~~891		)	~~527~~617,~~070~~560
Long-term debt, net of current installments and discount	—		4,780,663			—		—		—			4,780,663
Long-term debt, net of current installments, discount and debt issuance costs	—		4,820,113			—		—		—			4,820,113
Non-current tax liabilities	—		915,~~646~~259			615,~~306~~287		183,~~434~~148		—			3433,~~386~~694
Deferred income taxes	—		6655,~~732~~359			~~688~~603,~~665~~250		4339,~~020~~862		—			~~798~~698,~~417~~471
Other non-current liabilities	~~753~~909		3028,~~717~~451			482,~~799~~459		2,~~682~~790		—			8234,~~951~~609
Intercompany loan payables	—		~~429~~435,~~482~~607			~~745~~735,000		34,~~799~~330		(1,~~178~~174,~~281~~937		)	—
Total liabilities	10,306		7,209,114			4,439,246		678,710		(6,113,889		)	6,223,487
Intercompany advance	—		—			1,241		—		(1,241		)	—
Total equity	620,107		(501,640		)	1,524,140		704,271		(1,726,771		)	620,107
Total liabilities	11,241		7,481,810			4,489,038		671,427		(6,449,069		)	6,204,447
	$	630,413	$	6,707,474		$	5,963,386	$	1,382,981	$	(7,840,660	)	$	6,843,594
Total equity	581,753		(723,863		)	1,498,115		626,846		(1,401,098		)	581,753
	$	592,994	$	6,757,947		$	5,987,153	$	1,298,273	$	(7,850,167	)	$	6,786,200

1923

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Balance Sheet

December 31, ~~2014~~2015

(in thousands)

	Acelity L.P. Inc. Parent Company		Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Consolidated
Assets:
Current assets:
Cash and cash equivalents	$	398	$	4112,~~027~~859		$	14,~~499~~919	$	~~140~~70,~~617~~233	$	—		$	~~183~~88,~~541~~409
Accounts receivable, net	—		~~179~~202,~~872~~377			6758,~~355~~080		~~123~~153,~~256~~074		—			~~370~~413,~~483~~531
Inventories, net	—		7389,~~904~~929			~~110~~87,~~355~~519		93104,~~765~~904		(99101,~~802~~043		)	~~178~~181,~~222~~309
Deferred income taxes	—		5266,~~868~~235			108,~~157~~286		—		—			6374,~~025~~521
Prepaid expenses and other	—		1115,~~106~~199			67,~~851~~519		~~247~~244,~~606~~833		(~~238~~232,~~000~~566		)	2734,~~563~~985
Intercompany receivables	166		12,~~854~~098,~~033~~061			2,~~432~~828,~~299~~639		4816,~~267~~279		(4,~~334~~943,~~765~~145		)	—
Total current assets	564		2,~~212~~484,~~810~~660			2,~~628~~994,~~516~~962		~~653~~589,~~511~~323		(45,~~672~~276,~~567~~754		)	~~822~~792,~~834~~755
Net property, plant and equipment	—		~~315~~294,~~691~~855			6959,~~801~~833		~~164~~127,~~838~~858		(~~262~~209,~~282~~470		)	~~288~~273,~~048~~076
Debt issuance costs, net	—		77,896			—		—		—			77,896
Deferred income taxes	—		—			—		29,909		—			29,909
Deferred income taxes	—		—			—		31,692		—			31,692
Goodwill	—		2,510,765			732,138		162,920		—			3,405,823
Goodwill	—		2,483,240			732,138		162,920		—			3,378,298
Identifiable intangible assets, net	—		250,635			1,704,521		263,932		—			2,219,088
Identifiable intangible assets, net	—		299,575			1,788,661		309,015		—			2,397,251
Other non-current assets	—		1,029			282		4,793		—			6,104
Other non-current assets	—		1,161			186		94,247		(90,900		)	4,694
Intercompany loan receivables	—		740,000			436,432		—		(1,176,432		)	—
Intercompany loan receivables	—		760,000			429,856		—		(1,189,856		)	—
Intercompany investments	613,540		353,768			—		—		(967,308		)	—
Intercompany investments	667,530		360,292			223,581		—		(1,251,403		)	—
	$	614,104	$	6,635,712		$	5,928,168	$	1,178,735	$	(7,629,964	)	$	6,726,755
	$	668,094	$	6,510,665		$	5,872,739	$	1,416,223	$	(7,467,008	)	$	7,000,713
Liabilities and Equity:
Current liabilities:
Accounts payable	$	~~245~~—	$	1618,~~298~~013		$	14,~~463~~129	$	2025,~~821~~768	$	—		$	5157,~~827~~910
Accrued expenses and other	—		~~218~~234,~~793~~036			~~244~~260,~~829~~404		7468,~~380~~207		(~~194~~189,~~518~~207		)	~~343~~373,~~484~~440
Intercompany payables	610,~~441~~115		1,~~181~~730,~~383~~435			2,~~634~~689,~~149~~502		~~512~~513,~~792~~093		(4,~~334~~943,~~765~~145		)	—
Current installments of long-term debt	—		2522,~~721~~130			—		—		—			2522,~~721~~130
Income taxes payable	—		—			—		13,~~305~~561		—			13,~~305~~561
Deferred income taxes	—		—			113,~~658~~595		—		—			113,~~658~~595
Total current liabilities	610,~~686~~115		12,~~442~~004,~~195~~614			3,~~007~~077,~~099~~630		~~609~~610,~~298~~629		(45,~~529~~132,~~283~~352		)	~~535~~570,~~995~~636
Long-term debt, net of current installments and discount	—		4,815,290			—		—		—			4,815,290
Long-term debt, net of current installments, discount and debt issuance costs	—		4,720,363			—		—		—			4,720,363
Non-current tax liabilities	—		915,~~404~~046			614,~~203~~965		174,~~693~~822		—			3334,~~300~~833
Deferred income taxes	—		~~106~~110,~~440~~076			~~637~~609,~~777~~281		4741,~~940~~380		—			~~792~~760,~~157~~737
Other non-current liabilities	~~695~~824		~~113~~29,~~368~~079			484,~~172~~472		12,~~023~~646		—			~~163~~37,~~258~~021
Intercompany loan payables	—		~~420~~432,~~294~~545			~~760~~740,000		93,~~562~~887		(1,~~189~~176,~~856~~432		)	—
Total liabilities	7,381		6,906,991			4,459,251		685,516		(5,719,139		)	6,340,000
Intercompany advance	—		—			70,045		—		(70,045		)	—
Total equity	660,713		(396,326		)	1,413,488		730,707		(1,747,869		)	660,713
Total liabilities	10,939		7,311,723			4,516,393		663,364		(6,378,829		)	6,123,590
	$	668,094	$	6,510,665		$	5,872,739	$	1,416,223	$	(7,467,008	)	$	7,000,713
Total equity	603,165		(676,011		)	1,411,775		515,371		(1,251,135		)	603,165
	$	614,104	$	6,635,712		$	5,928,168	$	1,178,735	$	(7,629,964	)	$	6,726,755

2024

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the three months ended September 30, 2015
	For the three months ended March 31, 2016
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	~~164~~150,~~284~~420		$	—		$	2119,~~668~~679		$	—		$	~~185~~170,~~952~~099
Sales	—			9190,~~638~~781			~~220~~245,~~649~~943			~~195~~251,~~760~~262			(~~216~~306,~~319~~719		)	~~291~~281,~~728~~267
Total revenue	—			~~255~~241,~~922~~201			~~220~~245,~~649~~943			~~217~~270,~~428~~941			(~~216~~306,~~319~~719		)	~~477~~451,~~680~~366
Rental expenses	2120			7981,~~983~~488			~~2,729~~176			3735,~~721~~951			(4342,~~829~~740		)	7674,~~625~~895
Cost of sales	14—			9399,~~444~~612			~~135~~160,~~240~~795			8492,~~654~~681			(~~236~~274,~~423~~509		)	7678,~~929~~579
Gross profit (loss)	(3520		)	8260,~~495~~101			8284,~~680~~972			95142,~~053~~309			6310,~~933~~530			~~324~~297,~~126~~892
Selling, general and administrative expenses	~~1,026~~748			7780,~~673~~974			3842,~~425~~374			4340,~~173~~733			(~~341~~385		)	~~159~~164,~~956~~444
Research and development expenses	—			5,~~324~~764			5,~~251~~019			3,~~418~~195			~~278~~—			1413,~~271~~978
Acquired intangible asset amortization	—			1211,~~753~~584			19,~~175~~364			11,~~917~~254			—			4342,~~845~~202
Operating earnings (loss)	(~~1,061~~768		)	(1338,~~255~~221		)	1918,~~829~~215			3687,~~545~~127			6310,~~996~~915			~~106~~77,~~054~~268
Non-operating intercompany transactions	—			5(1,~~504~~402		)	146,~~472~~713			(205,~~015~~352		)	3941			—
Interest income and other	—			16,~~914~~508			37,~~063~~617			2971			(1924,~~938~~089		)	68107
Interest expense	—			(~~109~~116,~~592~~088		)	(16,~~874~~537		)	(8116		)	1924,~~938~~089			(~~106~~108,~~609~~552		)
Foreign currency gain (loss)	—			(666		)	(1,717		)	(6,806		)	—			(9,189		)
Loss on extinguishment of debt	—			(3,609		)	—			—			—			(3,609		)
Derivative instruments loss	—			(869		)	—			—			—			(869		)
Foreign currency gain (loss)	—			(13,044		)	737			7,977			—			(4,330		)
Earnings (loss) from continuing operations before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(1,061		)	(101,964		)	18,773			9,672			64,035			(10,545		)
Derivative instruments loss	—			(682		)	—			—			—			(682		)
Income tax expense (benefit)	—			6,399			(7,419		)	427			—			(593		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(768		)	(156,538		)	16,745			89,807			10,956			(39,798		)
Earnings (loss) from continuing operations before equity in earnings (loss) of subsidiaries	(1,061		)	(108,363		)	26,192			9,245			64,035			(9,952		)
Income tax expense (benefit)	—			(33,980		)	(846		)	21,003			—			(13,823		)
Equity in earnings (loss) of subsidiaries	(8,891		)	33,709			9,245			—			(34,063		)	—
Earnings (loss) before equity in earnings (loss) of subsidiaries	(768		)	(122,558		)	17,591			68,804			10,956			(25,975		)
Earnings (loss) from continuing operations	(9,952		)	(74,654		)	35,437			9,245			29,972			(9,952		)
Equity in earnings (loss) of subsidiaries	(25,207		)	74,464			68,804			—			(118,061		)	—
Earnings (loss) from discontinued operations, net of tax	—			—			—			—			—			—
Net earnings (loss)	$	(25,975	)	$	(48,094	)	$	86,395		$	68,804		$	(107,105	)	$	(25,975	)
Net earnings (loss)	$	(9,952	)	$	(74,654	)	$	35,437		$	9,245		$	29,972		$	(9,952	)
Total comprehensive income (loss)	$	(21,877	)	$	(43,996	)	$	90,493		$	72,902		$	(119,399	)	$	(21,877	)
Total comprehensive income (loss)	$	(15,749	)	$	(80,451	)	$	29,640		$	3,448		$	47,363		$	(15,749	)

2125

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the three months ended September 30, 2014
	For the three months ended March 31, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	~~160~~149,~~147~~698		$	—		$	2823,~~696~~141		$	—		$	~~188~~172,~~843~~839
Sales	—			7983,~~951~~737			~~265~~239,~~930~~691			~~239~~229,~~133~~663			(~~292~~281,~~064~~880		)	~~292~~271,~~950~~211
Total revenue	—			~~240~~233,~~098~~435			~~265~~239,~~930~~691			~~267~~252,~~829~~804			(~~292~~281,~~064~~880		)	~~481~~444,~~793~~050
Rental expenses	—21			7675,~~656~~873			3,~~680~~467			4941,~~544~~365			(4642,~~299~~548		)	8378,~~581~~178
Cost of sales	2843			8789,~~277~~496			~~178~~159,~~262~~253			9187,~~044~~974			(~~272~~263,~~812~~352		)	8373,~~799~~414
Gross profit (loss)	(2864		)	7668,~~165~~066			8376,~~988~~971			~~127~~123,~~241~~465			2724,~~047~~020			~~314~~292,~~413~~458
Selling, general and administrative expenses	~~835~~471			7268,~~295~~519			4236,~~769~~716			4642,~~583~~308			(~~213~~251		)	~~162~~147,~~269~~763
Research and development expenses	—			5,~~771~~617			64,~~130~~896			34,~~978~~165			—			1514,~~879~~678
Acquired intangible asset amortization	—			1513,~~077~~880			19,~~731~~456			1312,~~110~~541			—			4745,~~918~~877
Operating earnings (loss)	(~~863~~535		)	(1619,~~978~~950		)	15,~~358~~903			6364,~~570~~451			2724,~~260~~271			8884,~~347~~140
Non-operating intercompany transactions	—			5(1,~~702~~682		)	~~(895~~30,849		)	(1529,~~994~~190		)	~~11,187~~23			—
Interest income and other	—			1816,~~955~~762			3,~~062~~063			88103			(2219,~~082~~781		)	23147
Interest expense	—			(107,~~529~~782		)	(1716,~~305~~718		)	(~~1,723~~7		)	2219,~~082~~781			(104,~~475~~726		)
Foreign currency gain (loss)	—			2735,~~996~~006			(~~783~~1,593		)	(1714,~~614~~013		)	—			919,~~599~~400
Derivative instruments loss	—			1(3,~~630~~348		)	—			—			—			1(3,~~630~~348		)
Earnings (loss) from continuing operations before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(863		)	(70,224		)	(563		)	28,327			38,447			(4,876		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(535		)	(80,994		)	31,504			21,344			24,294			(4,387		)
Income tax expense (benefit)	—			~~12,787~~415			~~(12,164~~141		)	(~~2,264~~412		)	—			~~(1,641~~144		)
Earnings (loss) from continuing operations before equity in earnings (loss) of subsidiaries	(863		)	(83,011		)	11,601			30,591			38,447			(3,235		)
Earnings (loss) before equity in earnings (loss) of subsidiaries	(535		)	(81,409		)	31,363			21,756			24,294			(4,531		)
Equity in earnings (loss) of subsidiaries	(~~974~~3,996		)	4448,~~971~~953			3021,~~591~~756			—			(7466,~~588~~713		)	—
Earnings (loss) from continuing operations	(1,837		)	(38,040		)	42,192			30,591			(36,141		)	(3,235		)
Net earnings (loss)	$	(4,531	)	$	(32,456	)	$	53,119		$	21,756		$	(42,419	)	$	(4,531	)
Earnings (loss) from discontinued operations, net of tax	—			—			1,398			—			—			1,398
Total comprehensive income (loss)	$	(11,602	)	$	(39,527	)	$	46,048		$	14,685		$	(21,206	)	$	(11,602	)
Net earnings (loss)	$	(1,837	)	$	(38,040	)	$	43,590		$	30,591		$	(36,141	)	$	(1,837	)
Total comprehensive income (loss)	$	(5,919	)	$	(42,122	)	$	39,508		$	26,509		$	(23,895	)	$	(5,919	)

2226

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the nine months ended September 30, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	471,656		$	—		$	67,532		$	—		$	539,188
Sales	—			263,342			678,080			628,514			(725,749		)	844,187
Total revenue	—			734,998			678,080			696,046			(725,749		)	1,383,375
Rental expenses	57			233,063			8,869			119,946			(129,263		)	232,672
Cost of sales	67			273,659			431,430			257,652			(736,956		)	225,852
Gross profit (loss)	(124		)	228,276			237,781			318,448			140,470			924,851
Selling, general and administrative expenses	2,242			221,019			115,465			128,684			(697		)	466,713
Research and development expenses	—			16,186			15,790			11,086			278			43,340
Acquired intangible asset amortization	—			39,937			57,944			36,553			—			134,434
Operating earnings (loss)	(2,366		)	(48,866		)	48,582			142,125			140,889			280,364
Non-operating intercompany transactions	—			26,358			234,292			(260,832		)	182			—
Interest income and other	—			50,475			12,461			184			(62,838		)	282
Interest expense	—			(331,047		)	(50,390		)	(110		)	62,838			(318,709		)
Foreign currency gain (loss)	—			24,129			(2,615		)	(18,102		)	—			3,412
Derivative instruments gain	—			(5,136		)	—			—			—			(5,136		)
Earnings (loss) from continuing operations before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(2,366		)	(284,087		)	242,330			(136,735		)	141,071			(39,787		)
Income tax expense (benefit)	—			(2,638		)	(8,584		)	3,549			—			(7,673		)
Earnings (loss) from continuing operations before equity in earnings (loss) of subsidiaries	(2,366		)	(281,449		)	250,914			(140,284		)	141,071			(32,114		)
Equity in earnings (loss) of subsidiaries	(29,748		)	102,386			(140,284		)	—			67,646			—
Earnings (loss) from continuing operations	(32,114		)	(179,063		)	110,630			(140,284		)	208,717			(32,114		)
Loss from discontinued operations, net of tax	—			—			—			—			—			—
Net earnings (loss)	$	(32,114	)	$	(179,063	)	$	110,630		$	(140,284	)	$	208,717		$	(32,114	)
Total comprehensive income (loss)	$	(40,047	)	$	(186,996	)	$	102,697		$	(148,217	)	$	232,516		$	(40,047	)

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the nine months ended September 30, 2014
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	440,351		$	—		$	87,098		$	—		$	527,449
Sales	—			215,289			714,000			665,333			(738,465		)	856,157
Total revenue	—			655,640			714,000			752,431			(738,465		)	1,383,606
Rental expenses	80			216,134			9,008			157,584			(128,687		)	254,119
Cost of sales	73			229,191			453,774			274,514			(712,281		)	245,271
Gross profit (loss)	(153		)	210,315			251,218			320,333			102,503			884,216
Selling, general and administrative expenses	2,813			224,598			131,151			149,470			(386		)	507,646
Research and development expenses	—			17,634			19,409			14,559			—			51,602
Acquired intangible asset amortization	—			47,239			59,621			40,501			—			147,361
Wake Forest settlement	—			198,578			—			—			—			198,578
Operating earnings (loss)	(2,966		)	(277,734		)	41,037			115,803			102,889			(20,971		)
Non-operating intercompany transactions	—			5,034			(29,421		)	(46,983		)	71,370			—
Interest income and other	—			53,456			15,953			165			(69,329		)	245
Interest expense	—			(324,379		)	(51,663		)	(1,762		)	69,329			(308,475		)
Foreign currency gain (loss)	—			31,375			(480		)	(17,208		)	—			13,687
Derivative instruments gain (loss)	—			(2,670		)	—			—			—			(2,670		)
Earnings (loss) from continuing operations before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(2,966		)	(514,918		)	(24,574		)	50,015			174,259			(318,184		)
Income tax expense (benefit)	—			(177,652		)	43,205			20,381			—			(114,066		)
Earnings (loss) from continuing operations before equity in earnings (loss) of subsidiaries	(2,966		)	(337,266		)	(67,779		)	29,634			174,259			(204,118		)
Equity in earnings (loss) of subsidiaries	(197,971		)	(39,793		)	29,634			—			208,130			—
Earnings (loss) from continuing operations	(200,937		)	(377,059		)	(38,145		)	29,634			382,389			(204,118		)
Earnings (loss) from discontinued operations, net of tax	—			—			3,181			—			—			3,181
Net earnings (loss)	$	(200,937	)	$	(377,059	)	$	(34,964	)	$	29,634		$	382,389		$	(200,937	)
Total comprehensive income (loss)	$	(204,834	)	$	(380,956	)	$	(38,861	)	$	25,737		$	394,080		$	(204,834	)

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Cash Flows

(in thousands)

(unaudited)

	For the nine months ended September 30, 2015
	For the three months ended March 31, 2016
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash flows from operating activities:
Net earnings (loss)	$	(3225,~~114~~975	)	$	(~~179~~48,~~063~~094	)	$	~~110~~86,~~630~~395		$	~~(140~~68,~~284~~804	)	$	~~208~~(107,~~717~~105	)	$	(3225,~~114~~975	)
Adjustments to reconcile net earnings (loss) to net cash provided (used) by operating activities	~~5,233~~985			~~300~~144,~~215~~348			(~~137,018~~389		)	81(23,~~591~~268		)	(~~107~~17,~~897~~516		)	~~142~~104,~~124~~160
Net cash provided (used) by operating activities	(2624,~~881~~990		)	~~121~~96,~~152~~254			~~(26~~86,~~388~~006		)	~~(58~~45,~~693~~536		)	~~100~~(124,~~820~~621		)	~~110~~78,~~010~~185
Cash flows from investing activities:
Net additions to property, plant and equipment	—			(~~107~~49,~~919~~827		)	(43,~~461~~842		)	(1810,~~434~~099		)	8445,~~506~~320			(4618,~~308~~448		)
Businesses acquired in purchase transactions, net of cash acquired	—			—			—			(2,948		)	—			(2,948		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(88		)	(2,260		)	1,219			—			(1,129		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(70		)	(6,280		)	849			—			(5,501		)
Net cash provided (used) by investing activities	—			(49,915		)	(6,102		)	(8,880		)	45,320			(19,577		)
Net cash provided (used) by investing activities	—			(107,989		)	(10,741		)	(20,533		)	84,506			(54,757		)
Cash flows from financing activities:
Distribution to limited partners	(55		)	—			—			—			—			(55		)
Settlement of profits interest units	(217		)	—			—			—			—			(217		)
Settlement of profits interest units	(2,812		)	—			—			—			—			(2,812		)
Proceeds from first lien senior secured notes	—			400,000			—			—			—			400,000
Proceeds from revolving credit facility	—			30,000			—			—			—			30,000
Repayments of long-term debt and capital lease obligations	—			(317,731		)	—			—			—			(317,731		)
Repayments of long-term debt and other financing obligations	—			(49,391		)	(5,000		)	19			—			(54,372		)
Debt issuance costs	—			(8,407		)	—			—			—			(8,407		)
Debt issuance costs	—			(6,256		)	—			—			—			(6,256		)
Proceeds (payments) on intercompany loans	—			8,062			(8,505		)	443			—			—
Proceeds (payments) on intercompany loans	—			24,188			(18,425		)	(5,763		)	—			—
Proceeds (payments) on intercompany investments	25,207			(74,222		)	(68,860		)	38,574			79,301			—
Proceeds (payments) on intercompany investments	29,748			(28,636		)	62,434			121,780			(185,326		)	—
Net cash provided (used) by financing activities	24,990			7,702			(77,365		)	39,017			79,301			73,645
Net cash provided (used) by financing activities	26,881			(30,095		)	39,009			116,036			(185,326		)	(33,495		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			2,954			—			2,954
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(8,289		)	—			(8,289		)
Net increase (decrease) in cash and cash equivalents	—			54,041			2,539			78,627			—			135,207
Net increase (decrease) in cash and cash equivalents	—			(16,932		)	1,880			28,521			—			13,469
Cash and cash equivalents, beginning of period	398			12,859			4,919			70,233			—			88,409
Cash and cash equivalents, beginning of period	398			41,027			1,499			140,617			—			183,541
Cash and cash equivalents, end of period	$	398		$	66,900		$	7,458		$	148,860		$	—		$	223,616
Cash and cash equivalents, end of period	$	398		$	24,095		$	3,379		$	169,138		$	—		$	197,010

2527

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Cash Flows

(in thousands)

(unaudited)

	For the nine months ended September 30, 2014
	For the three months ended March 31, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash flows from operating activities:
Net earnings (loss)	$	(~~200~~4,~~937~~531	)	$	(~~377~~32,~~059~~456	)	$	~~(34~~53,~~964~~119	)	$	2921,~~634~~756		$	~~382~~(42,~~389~~419	)	$	(~~200~~4,~~937~~531	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities	41,~~381~~107			~~214~~48,~~293~~156			~~123~~52,~~273~~609			~~129~~15,~~300~~657			(~~165~~10,~~279~~047		)	~~305~~107,~~968~~482
Net cash provided (used) by operating activities	(~~196~~3,~~556~~424		)	~~(162~~15,~~766~~700		)	88105,~~309~~728			~~158~~37,~~934~~413			~~217~~(52,~~110~~466		)	~~105~~102,~~031~~951
Cash flows from investing activities:
Net additions to property, plant and equipment	—			(~~132~~26,~~506~~027		)	(32,~~688~~356		)	(311,~~367~~082		)	~~119~~15,~~763~~618			(4713,~~798~~847		)
Businesses acquired in purchase transactions, net of cash acquired	—			—			(4,500		)	(113		)	—			(4,613		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(130		)	(1,820		)	129			—			(1,821		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(419		)	(4,896		)	(4,036		)	—			(9,351		)
Net cash provided (used) by investing activities	—			(26,157		)	(4,176		)	(953		)	15,618			(15,668		)
Net cash provided (used) by investing activities	—			(132,925		)	(13,084		)	(35,516		)	119,763			(61,762		)
Cash flows from financing activities:
Settlement of profits interest units	(1,416		)	—			—			—			—			(1,416		)
Distribution to limited partners	(55		)	—			—			—			—			(55		)
Repayments of long-term debt and other financing obligations	—			(19,816		)	—			(47		)	—			(19,863		)
Settlement of profits interest units	(517		)	—			—			—			—			(517		)
Proceeds (payments) on intercompany loans	—			243,714			(33,736		)	(209,978		)	—			—
Repayments of long-term debt and capital lease obligations	—			(6,446		)	—			31			—			(6,415		)
Proceeds (payments) on intercompany investments	197,972			36,402			(32,162		)	134,661			(336,873		)	—
Payment of debt issuance costs	—			(6,256		)	—			—			—			(6,256		)
Net cash provided (used) by financing activities	196,556			260,300			(65,898		)	(75,364		)	(336,873		)	(21,279		)
Proceeds (payments) on intercompany loans	—			8,063			(6,770		)	(1,293		)	—			—
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(4,034		)	—			(4,034		)
Proceeds (payments) on intercompany investments	3,996			24,124			(96,281		)	31,313			36,848			—
Net increase (decrease) in cash and cash equivalents	—			(35,391		)	9,327			44,020			—			17,956
Net cash provided (used) by financing activities	3,424			19,485			(103,051		)	30,051			36,848			(13,243		)
Cash and cash equivalents, beginning of period	398			87,771			118			118,662			—			206,949
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(7,072		)	—			(7,072		)
Cash and cash equivalents, end of period	$	398		$	52,380		$	9,445		$	162,682		$	—		$	224,905
Net increase (decrease) in cash and cash equivalents	—			9,028			(1,499		)	59,439			—			66,968
Cash and cash equivalents, beginning of period	398			41,027			1,499			140,617			—			183,541
Cash and cash equivalents, end of period	$	398		$	50,055		$	—		$	200,056		$	—		$	250,509

2628

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the condensed consolidated financial statements and accompanying notes included in this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in our “Risk Factors” (Part II, Item 1A.), including those previously disseminated in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

~~GENERAL~~OVERVIEW

We are a leading global medical technology company committed to the development and commercialization of advanced wound care and regenerative medicine solutions. We were formed by uniting the strengths of three organizations, KCI, Systagenix and LifeCell, into our two business segments: Advanced Wound Therapeutics ("AWT") and Regenerative Medicine. Our mission is to change the clinical practice of medicine with solutions that speed healing, reduce complications, create economic value and improve patients’ lives. We offer a broad range of products that can be used across clinical applications, care settings and clinician groups to accelerate soft tissue healing, improve clinical outcomes and reduce overall costs of care. Our product offerings are backed by an extensive body of scientific, clinical and economic outcomes, data that demonstrate the clinical efficacy and value proposition of our products. By offering a range of complementary solutions that are often used together or in sequence across multiple care settings, we are able to address patients’ needs throughout the healing process and offer healthcare providers a single source for addressing such needs.

Our AWT business is focused on the development and commercialization of advanced devices and advanced wound dressings. Our advanced devices business is primarily engaged in marketing several technology platforms, including NPWT, surgical and incision management and epidermal grafting. For patients suffering from traumatic, surgical or chronic wounds, such as diabetic foot ulcers, our NPWT devices facilitate accelerated healing that was unattainable prior to the introduction of NPWT. Our advanced wound dressings business markets wound dressing technologies for the purpose of managing chronic and acute wounds. Our advanced wound dressings are designed to maintain a moist wound environment, while managing exudate, to promote healing and to protect the wound site from infection. Our AWT business is primarily conducted by KCI and its operating subsidiaries, including Systagenix.

Our Regenerative Medicine business is primarily focused on the development and commercialization of regenerative and reconstructive acellular tissue matrices for use in general and reconstructive surgical procedures to reinforce soft tissue defects. We offer tissue matrices for a variety of reconstructive procedures, including post-mastectomy breast reconstruction and the reinforcement of abdominal wall defects. Our tissue matrices are engineered to encourage rapid tissue incorporation, reducing morbidity for patients, while providing optimal reconstructive outcomes. In addition to our acellular tissue matrices, our Regenerative Medicine business markets complementary autologous fat grafting solutions for reconstructive and aesthetic applications. Our Regenerative Medicine business is primarily conducted by LifeCell and its operating subsidiaries.

We are a global company with approximately 2624% of our revenues generated outside the United States infor the ~~third~~three ~~quarter~~months ~~and~~ended ~~first~~March ~~nine~~31, ~~months of 2015~~2016, and our products are available in ~~more~~approximately ~~than~~80 75 countries. We have invested in direct sales and marketing channels and distributors in order to expand our presence in these markets to meet the needs of our customers and payers across clinical applications, care settings and clinician groups. A critical component of marketing our portfolio of solutions and services is our sales organization of approximately 1,800 professionals working across multiple care settings and specialties. This sales infrastructure enables us to market our products directly with trained medical professionals in specific care settings in the United States, Canada, Western Europe and key emerging markets. We also have established strong relationships globally with key constituencies, including hospitals, post-acute facilities, group purchasing organizations, or GPOs, payers and other key clinical and economic decision makers by offering comprehensive customer service and clinical education.

We have two reportable operating segments which correspond to our two businesses: AWT and Regenerative Medicine. We also have other revenue which consists of contract manufacturing operations performed at our manufacturing facility in Gargrave, England.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, our results of operations (dollars in thousands):

	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Revenue:
Rental	$	185,952		$	188,843		$	539,188		$	527,449
Sales	291,728			292,950			844,187			856,157
Total revenue	477,680			481,793			1,383,375			1,383,606
Rental expenses	76,625			83,581			232,672			254,119
Cost of sales	76,929			83,799			225,852			245,271
Gross profit	324,126			314,413			924,851			884,216
Gross profit margin	67.9		%	65.3		%	66.9		%	63.9		%
Selling, general and administrative expenses	159,956			162,269			466,713			507,646
Research and development expenses	14,271			15,879			43,340			51,602
Acquired intangible asset amortization	43,845			47,918			134,434			147,361
Wake Forest settlement	—			—			—			198,578
Operating earnings (loss)	106,054			88,347			280,364			(20,971		)
Operating profit margin	22.2		%	18.3		%	20.3		%	(1.5		)%
Interest income and other	68			23			282			245
Interest expense	(106,609		)	(104,475		)	(318,709		)	(308,475		)
Foreign currency gain (loss)	(9,189		)	9,599			3,412			13,687
Derivative instruments gain (loss)	(869		)	1,630			(5,136		)	(2,670		)
Loss from continuing operations before income tax benefit	(10,545		)	(4,876		)	(39,787		)	(318,184		)
Income tax benefit	(593		)	(1,641		)	(7,673		)	(114,066		)
Effective tax rate	5.6		%	33.7		%	19.3		%	35.8		%
Loss from continuing operations	(9,952		)	(3,235		)	(32,114		)	(204,118		)
Earnings from discontinued operations, net of tax	—			1,398			—			3,181
Net loss	$	(9,952	)	$	(1,837	)	$	(32,114	)	$	(200,937	)

Revenue

Total revenue for the third quarter of 2015 decreased $4.1 million, or 0.9%, as reported on a GAAP basis, and increased 16.0 million, or 3.3%, on a constant currency basis, compared to the prior year period. Total revenue for the first nine months of 2015 decreased $0.2 million as reported on a GAAP basis, and increased $58.1 million or 4.2%, on a constant currency basis, compared to the prior year period. Excluding the impact of foreign currency exchange rate movements, the increases in total revenue compared to the prior year periods were due to higher AWT and Regenerative Medicine revenue.

Revenue by Operating Segment

The following table sets forth, for the periods indicated, segment revenue and the percentage changes in each line item between the periods (dollars in thousands):

	Three months ended September 30,
	2015		2015		2014		As Reported		Constant Currency
	(GAAP)		(Constant currency)		(GAAP)		% Change		% Change (1)
Advanced Wound Therapeutics revenue:
Rental	$	185,952	$	189,832	$	188,843	(1.5	)%	0.5	%
Sales	179,867		194,512		184,122		(2.3	)	5.6
Total – Advanced Wound Therapeutics	365,819		384,344		372,965		(1.9	)	3.1
Regenerative Medicine revenue:
Sales	109,332		110,757		104,611		4.5		5.9
Other revenue:
Sales	2,529		2,725		4,217		(40.0	)	(35.4	)
Total consolidated revenue:
Rental	185,952		189,832		188,843		(1.5	)	0.5
Sales	291,728		307,994		292,950		(0.4	)	5.1
Total consolidated revenue	$	477,680	$	497,826	$	481,793	(0.9	)%	3.3	%

(1) Represents percentage change between non-GAAP constant currency revenue and GAAP revenue from the prior year. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We calculate constant currency by calculating current-period results using prior-period foreign currency exchange rates.

~~The~~Strategic ~~following table sets forth, for the periods indicated, segment revenue and the percentage changes in each line item between the periods (dollars in thousands):~~Transformation

	Nine months ended September 30,
	2015		2015		2014		As Reported		Constant Currency
	(GAAP)		(Constant currency)		(GAAP)		% Change		% Change (1)
Advanced Wound Therapeutics revenue:
Rental	$	539,188	$	550,706	$	527,449	2.2	%	4.4	%
Sales	518,104		559,736		523,784		(1.1	)	6.9
Total – Advanced Wound Therapeutics	1,057,292		1,110,442		1,051,233		0.6		5.6
Regenerative Medicine revenue:
Sales	317,030		321,365		318,791		(0.6	)	0.8
Other revenue:
Sales	9,053		9,882		13,582		(33.3	)	(27.2	)
Total consolidated revenue:
Rental	539,188		550,706		527,449		2.2		4.4
Sales	844,187		890,983		856,157		(1.4	)	4.1
Total consolidated revenue	$	1,383,375	$	1,441,689	$	1,383,606	—	%	4.2	%

Since our 2011 LBO, we have transformed our business strategically, operationally and financially. This transformation resulted from the re-alignment of our product portfolio through acquisitions and divestitures, expansion into developed and emerging markets, increased commitment to product innovation and new product launches and cost saving initiatives. Our transformation culminated in the unification of the businesses of KCI, LifeCell and Systagenix under our Acelity brand, designed to allow us to leverage our complementary product portfolio with our sales, marketing and distribution network to improve our go-to-market approach, drive increased market penetration through cross-selling opportunities and improve sales productivity across our platform.

~~(1)~~We ~~Represents~~initiated ~~percentage~~this ~~change~~transformation ~~between~~in ~~non-GAAP~~response ~~constant~~to ~~currency~~trends ~~revenue~~ and ~~GAAP~~challenges ~~revenue~~impacting ~~from~~our business and the ~~prior~~industry ~~year~~in which we operate. ~~Constant~~We ~~currency~~have ~~information~~managed ~~compares~~our ~~results~~business ~~between~~in ~~periods~~order asto iftake ~~exchange~~advantage ~~rates~~of ~~had~~the ~~remained~~growing ~~constant~~global ~~period-over-period.~~market Weopportunities ~~calculate~~for ~~constant~~our ~~currency~~AWT byand ~~calculating~~Regenerative ~~current-period~~Medicine ~~results~~products, ~~using~~driven ~~prior-period~~by ~~foreign~~the ~~currency~~following ~~exchange~~key ~~rates.~~growth drivers:

~~The~~• ~~following~~Favorable ~~table~~Global ~~sets~~Demographics ~~forth,~~and ~~for~~Aging ~~the~~Population. ~~periods~~The ~~indicated,~~global ~~the~~population ~~percentage~~aged ~~relationship~~65 ofand ~~each~~older ~~item~~is expected to ~~total~~grow ~~revenue~~from approximately 610 million people in ~~the~~2015 ~~period~~to approximately 1.2 billion people by 2035. There is a strong correlation between age and more severe chronic and surgical wounds and increased frequency of hernia and other abdominal wall defects, as well as ~~the~~breast ~~changes~~cancer, inthus ~~each~~increasing ~~line~~demand ~~item:~~for wound care and soft tissue repair products.

	Three months ended September 30,							Nine months ended September 30,
	2015		2014		Change			2015		2014		Change
Advanced Wound Therapeutics revenue	76.6	%	77.4	%	(80	)	bps	76.4	%	76.0	%	40		bps
Regenerative Medicine revenue	22.9		21.7		120		bps	22.9		23.0		(10	)	bps
Other revenue	0.5		0.9		(40	)	bps	0.7		1.0		(30	)	bps
Total consolidated revenue	100.0	%	100.0	%				100.0	%	100.0	%
Rental revenue	38.9	%	39.2	%	(30	)	bps	39.0	%	38.1	%	90		bps
Sales revenue	61.1		60.8		30		bps	61.0		61.9		(90	)	bps
Total consolidated revenue	100.0	%	100.0	%				100.0	%	100.0	%

•

Greater Incidence of Obesity, Diabetes and Other Chronic Conditions. According to the World Health Organization, worldwide obesity has more than doubled since 1980, and in 2014, more than 1.9 billion adults, 18 years and older, were overweight, 600 million of whom were obese. The number of people with diabetes is expected to rise from 415 million in 2015 to 642 million by 2040. Obesity and diabetes can cause other chronic conditions, such as venous insufficiencies that can impair the healing process. Higher incidence of these chronic conditions and co-morbidities in turn lead to increased incidence and complexity of wounds. Obesity is also a contributing factor to the incidence of abdominal wall defects, driving demand for soft tissue repair products.

~~AWT~~• ~~revenue~~Increasing ~~for~~Acceptance ~~the third quarter~~ of ~~2015~~Innovative ~~decreased~~Technologies ~~$7.1 million, or 1.9%, as reported on a GAAP basis,~~ and ~~increased~~Protocols ~~$11.4~~for ~~million,~~Complex orWound 3Treatment.~~1%,~~ onEducation aand ~~constant~~awareness ~~currency~~of ~~basis, compared to~~ the ~~prior~~benefits ~~year~~of ~~period.~~new ~~AWT~~wound ~~revenue~~care ~~for~~technologies ~~the~~and ~~first~~proper ~~nine~~wound ~~months~~care ofprotocols ~~2015~~have increased ~~$6.1 million, or 0.6%,~~ as ~~reported~~medical oninstitutions ~~a GAAP basis,~~ and ~~$59.2~~professionals ~~million,~~look ~~or 5.6%, on a constant currency basis, compared~~ to ~~the~~reduce ~~prior~~healthcare ~~year~~costs ~~period. Foreign currency exchange rate movements unfavorably impacted AWT rental revenue~~ by ~~$3.9~~decreasing ~~million, or 2.0%, and $11.5 million, or 2.2%, in~~ the ~~third~~length ~~quarter and first nine months~~ of ~~2015,~~hospital ~~respectively,~~stays ~~compared~~and to the ~~prior~~risk ~~year~~of ~~periods~~infection. ~~Excluding~~This ~~the~~expanded ~~impact~~acceptance of ~~foreign~~best ~~currency~~practices ~~exchange~~has ~~rate~~resulted ~~movements,~~in ~~AWT~~a ~~rental~~shift ~~revenue~~away ~~for~~from ~~the~~traditional ~~third~~lower-technology ~~quarter~~wound ~~and~~care ~~first~~modalities ~~nine months of 2015 increased $1.0 million, or 0.5%,~~ and ~~$23.3 million, or 4.4%, respectively, compared to the prior year periods due primarily to increased NPWT volumes associated with~~ increasing ~~device~~demand ~~utilization~~for inadvanced ~~the~~wound ~~United~~care ~~States~~treatments ~~and~~backed ~~growth in device volumes internationally, partially offset~~ by ~~lower~~clinical ~~average pricing due to increased competition, healthcare reform~~ and economic evidence.

•

Increasing Awareness of and Demand for Biologics in Complex Soft Tissue Repair Procedures, such as Breast Reconstruction and Abdominal Wall Reconstruction. The increased incidence of breast cancer combined with rising awareness of post-mastectomy treatment options, including the significant psychological benefits of breast reconstruction, have resulted in increasing numbers of patients seeking breast reconstruction following mastectomy or lumpectomy. This is being driven by increasing surgeon awareness of the large body of published clinical data demonstrating better clinical outcomes from using biologic dermal matrices in soft tissue repair procedures.

•

Shift to Advanced Treatment Protocols Outside of the United States. In emerging markets, the incidence of chronic wounds continues to be under-addressed. As the middle class continues to grow in emerging markets, we expect there will be an increased adoption of advanced wound dressings due to access to better healthcare and greater awareness of the cost-effectiveness of advanced wound therapies for chronic wounds. In addition, in certain developed markets in Europe, there is increased momentum to provide healthcare in post-acute settings. As these post-acute settings develop further, we believe there will be increased adoption of advanced devices, including NPWT, and advanced wound dressings. While biologic dermal matrices are largely used in the United States for breast reconstruction and abdominal wall reconstruction procedures, synthetic meshes are currently more widely used outside the United States. As the awareness of benefits of biologic dermal matrices in the markets outside the United States increases, we expect that there will be increased adoption of biologic dermal matrices in soft tissue repair procedures in such markets.

~~declining~~We ~~reimbursement.~~have ~~Foreign~~also ~~currency~~managed ~~exchange~~our ~~rate movements unfavorably impacted~~ AWT ~~sales revenue by $14.6 million, or 7.9%,~~ and ~~$41.6~~Regenerative ~~million,~~Medicine orbusinesses ~~8.0%,~~ in ~~the~~light ~~third quarter and first nine months~~ of ~~2015, respectively, compared to~~ the ~~prior~~following year periods. Excluding the impact of foreign currency exchange rate movements, AWT sales revenue for the third quarter and first nine months of 2015 increased by $10.4 million, or 5.6%, and $36.0 million, or 6.9%, respectively, compared to the prior year period due primarily to increased sales volumes of AWT devices and dressings. Total global pricing and reimbursement declines for AWT devices totaled $21.7 million for the nine months ended September 30, 2015, compared to the prior year period.challenges:

~~Regenerative~~• ~~Medicine~~Decreasing ~~revenue~~Price ~~for~~and ~~the~~Reimbursement ~~third quarter of 2015 increased $4~~Levels.7 ~~million,~~We orhave ~~4.5%,~~experienced asdownward ~~reported~~pressure on aprice ~~GAAP basis,~~ and ~~$6.1~~reimbursement ~~million,~~levels orfor ~~5.9%,~~our onAWT adevices ~~constant~~primarily ~~currency~~in ~~basis, compared to~~ the ~~prior~~United ~~period.~~States ~~Regenerative~~and ~~Medicine~~Europe ~~revenue~~both ~~for~~from ~~the~~public ~~first~~and ~~nine~~private ~~months~~third-party ofpayers, ~~2015~~including ~~decreased~~government-funded ~~$1.8~~programs ~~million,~~such oras 0Medicare.~~6%,~~ asThese ~~reported~~decreased onpricing ~~a GAAP basis,~~ and ~~increased~~reimbursement ~~$2.6~~levels ~~million~~have orresulted ~~0.8%,~~from on a ~~constant~~variety ~~currency~~of ~~basis~~factors, ~~compared~~including tostrategic ~~the~~pricing ~~prior~~reductions ~~year~~in ~~period. Foreign currency~~ exchange ~~rate~~for ~~movements~~longer-term ~~unfavorably~~contracts ~~impacted~~and ~~Regenerative~~other ~~Medicine~~favorable ~~revenue~~contract ~~by $1.4 million~~terms, orhealthcare ~~1.4%~~reform, ~~and~~government ~~$4.3~~austerity ~~million~~measures, orMedicare’s ~~1.4%,~~durable inmedical ~~the~~equipment ~~third~~competitive ~~quarter~~bidding program and ~~first nine months of 2015, respectively, compared to~~ the ~~prior year periods. Excluding the~~ impact of ~~foreign exchange rate movements,~~ the ~~increase~~U.S. ingovernment’s Regenerative Medicine revenue from the prior year periods was due primarily to growth in Strattice sales in our international markets and an increase in revenue related to breast reconstruction procedures, partially offset by a decline in revenue from abdominal wall reconstruction proceduressequestration.

~~Other~~• ~~revenue~~Cost ~~for~~Containment ~~the~~Efforts ~~third~~of ~~quarter~~Payers. ~~and~~The ~~first~~consolidation ~~nine months~~ of ~~2015~~our ~~decreased~~customers ~~$1.7~~into ~~million~~larger ~~and~~purchasing ~~$4.5~~groups, ~~million~~such as ~~reported~~GPOs onand aIDNs, ~~GAAP~~has ~~basis,~~increased ~~respectively,~~their negotiating and ~~decreased~~purchasing $1power.5 ~~million~~This ~~and~~trend, ~~$3.7~~in ~~million~~turn, onhas aresulted ~~constant~~in ~~currency~~increasing ~~basis,~~pricing ~~respectively,~~pressure ~~compared~~on us due to the ~~prior~~consolidation ~~year~~of ~~periods.~~healthcare ~~Other~~facilities, ~~revenue~~purchasing ~~consists~~groups ofand ~~contract~~U.S.-based ~~manufacturing~~insurance ~~revenue~~third ~~from~~party ~~our~~payers, ~~manufacturing~~pricing ~~plant~~concessions inand ~~Gargrave~~other cost containment efforts, ~~England~~such as competitive bidding processes.

~~Gross~~• ~~Profit~~Increased ~~and~~Competition. ~~Gross~~We ~~Profit~~have ~~Margin~~faced increased competition due to increased number of entrants into our key markets.

~~The~~As ~~following~~a ~~table~~result ~~presents~~of these market pressures, our overall pricing and reimbursement levels for AWT devices have declined. For the ~~gross~~years ~~profit~~ended December 31, 2015, 2014 and ~~gross~~2013, ~~profit~~we ~~margin~~estimate ~~(calculated~~global aspricing ~~gross~~and ~~profit~~reimbursement ~~divided~~declines for AWT devices totaled $38.7 million, $80.0 million and $42.6 million, respectively. A component of these declines was the impact associated with Medicare’s durable medical equipment competitive bidding program and the U.S. government’s sequestration, which together reduced Medicare reimbursement by ~~total~~$2.8 ~~revenue)~~million, $25.0 million and $14.8 million for the ~~periods~~years ~~indicated~~ended ~~(dollars~~December 31, in2015, ~~thousands):~~2014 and 2013, respectively.

	Three months ended September 30,								Nine months ended September 30,
	2015			2014			Change		2015			2014			Change
Gross profit	$	324,126		$	314,413		3.1%		$	924,851		$	884,216		4.6%
Gross profit margin	67.9		%	65.3		%	260	bps	66.9		%	63.9		%	300	bps

We expect that Medicare’s competitive bidding program and related price reductions in 2016 will further adversely impact our revenues in 2016 and 2017. Our total 2015 U.S. Medicare revenue was approximately 6.7%, or $124.6 million, of our global revenue. Of this amount, regions representing approximately $73.5 million in 2015 revenue are subject to an estimated overall price reduction of approximately 45% based on fee schedules announced by CMS in 2015, with approximately half of the reduction effective in January 2016, and the remainder effective in July 2016. In addition, our 2015 revenue from regions subject to Round Two of the competitive bidding program was approximately $43.7 million. In March 2016, CMS announced new single payment amounts, which represent average pricing reductions of approximately 13% in these regions, effective July 2016. In April 2016, we were informed that KCI was not awarded any contracts in the Round Two regions based on a technical disqualification. We plan to engage in discussions with CMS to seek reconsideration of this decision and are also evaluating various alternatives to provide continued patient access to our products in affected regions. Finally, 2015 revenue from regions subject to Round One of the competitive bidding program of $7.4 million will be subject to pricing changes resulting from the next round of the competitive bidding program, which will become effective January 2017.

~~Gross~~As ~~profit~~part ~~margin~~of ~~increased~~our byefforts ~~260 basis points~~ to ~~67.9%~~address insuch ~~the~~challenges, ~~third~~trends ~~quarter~~ and ~~300 basis points to 66.9% in the first nine months of 2015 from 65.3% and 63.9%~~uncertainties, ~~respectively,~~we inhave ~~the~~taken ~~prior year periods. The improvement in~~ the ~~gross~~following ~~profit~~actions ~~margin~~since ~~during~~our ~~the~~acquisition ~~third~~by ~~quarter and first nine months of 2015 compared to~~ the ~~prior-year periods was primarily due to the reduced impact of purchase accounting adjustments on rental expense and improved production yields, primarily in our Regenerative Medicine business.~~ Sponsors:

~~Cost~~• ofRealigning ~~sales~~our ~~for~~product ~~the~~portfolio ~~first~~and ~~nine~~expanding ~~months~~our ofaddressable ~~2015~~market ~~benefited~~by ~~from~~acquiring the ~~absence~~Systagenix ofwound ~~$6.7~~dressings ~~million~~business, ofsuccessfully ~~additional~~executing ~~cost of sales recorded~~ tuck-in ~~the~~technology ~~first~~acquisitions, ~~quarter~~such ofas ~~2014 associated with~~ the ~~step~~SNaP upNPWT inproduct ~~value~~portfolio, ofand ~~inventory~~divesting ~~associated~~our ~~with~~legacy ~~purchase~~lower ~~accounting. Foreign~~growth, ~~currency~~lower ~~exchange~~margin ~~rate~~Therapeutic ~~movements~~Support ~~favorably~~System, ~~impacted~~or ~~cost~~TSS, ofbusiness ~~sales for the third quarter~~ and ~~first~~SPY ~~nine~~Elite ~~months of 2015 by $4.2 million~~System, ~~and~~or ~~$12.2 million~~SPY, ~~respectively, compared to the prior year periods~~assets.

~~Rental~~• ~~expense~~Successfully ~~for~~commercializing ~~the~~new ~~third~~product ~~quarter~~categories ~~and~~such ~~first~~as ~~nine~~incision ~~months~~management, ofepidermal ~~2015~~skin ~~benefited~~grafting, ~~from~~fat ~~the~~grafting, ~~absence~~instillation ofNPWT, ~~$2.7 million~~ and ~~$16.2~~innovative ~~million~~customer ofservice ~~depreciation expense~~solutions, ~~respectively,~~including ~~related~~through to the ~~fixed~~launch ~~asset step-up associated with purchase accounting. Foreign currency exchange rate movements also favorably impacted rental expenses for the third quarter and first nine months~~ of ~~2015~~iOn byHealing ~~$4.6~~mobile ~~million and $14~~application.~~5 million, respectively, compared to the prior year periods, partially offset by increases in marketing and service-related expenses associated with increased rental revenue.~~


•	Investing in our commercial infrastructure by increasing our U.S. sales organization, expanding our distributor relationships in foreign countries and re-aligning our sales organization to better address the needs of our customers.


•	Expanding and deepening our global footprint through the acquisition of Systagenix which is based in the United Kingdom, as well as increasing market development and product introductions in Europe and emerging markets. Since 2011, we have increased our global presence and now market our products in approximately 80 countries.


•	Implementing a focused franchise model designed to better align our global research and development and marketing functions with our regional sales forces.

•

Implementing efficiencies in our systems and operations, which continue to drive significant and sustained cost savings. Such cost-savings initiatives consisted of centralizing our international management and our shared service operations into regional hubs in lower cost jurisdictions, integrating acquired businesses into our existing infrastructure, eliminating redundancy within the organization, creating a strategic procurement capability and lowering our costs through the identification of strategic suppliers and negotiation with them of mutually-advantageous contracts reflecting our integrated global purchasing scale and scope.

As a result of our transformation, we have strengthened our business, increased revenue and expanded margins by developing a unified and streamlined global business with product offerings across the continuum of care. These actions enabled us to stabilize our revenues in 2013 and begin to drive AWT revenue increases in 2014 and 2015, despite the pricing pressures in our industry. For the year ended December 31, 2015, global AWT devices volume increased revenue by $105.7 million, compared to an increase of $58.2 million in 2014. In addition, our business optimization and integration efforts have mitigated a considerable portion of the earnings impact relating to pricing headwinds and stranded costs from the sale of the TSS business. Over the past three years, we have realigned our organization following the sale of TSS and the purchase of the Systagenix business, while at the same time investing in commercial infrastructure, global footprint and building our franchise model. We believe these actions have established a solid foundation to support future growth and leverage our infrastructure in an effective and cost efficient manner.

Use of Constant Currency

As exchange rates are an important factor in understanding period-to-period comparisons, we believe in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this quarterly report on Form 10-Q , we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Results of Operations

The following table sets forth, for the periods indicated, our results of operations:



	Three months ended March 31,
($ in thousands)	2016			2015
Revenue:
Rental	$	170,099		$	172,839
Sales	281,267			271,211
Total revenue	451,366			444,050

Rental expenses	74,895			78,178
Cost of sales	78,579			73,414
Gross profit	297,892			292,458

Selling, general and administrative expenses	164,444			147,763
Research and development expenses	13,978			14,678
Acquired intangible asset amortization	42,202			45,877
Operating earnings	77,268			84,140

Interest income and other	107			147
Interest expense	(108,552		)	(104,726		)
Loss on extinguishment of debt	(3,609		)	—
Foreign currency gain (loss)	(4,330		)	19,400
Derivative instruments loss	(682		)	(3,348		)
Loss before income tax expense (benefit)	(39,798		)	(4,387		)
Income tax expense (benefit)	(13,823		)	144
Net loss	$	(25,975	)	$	(4,531	)

Revenue by Operating Segment

The following table sets forth, for the periods indicated, business unit revenue:



	Three months ended March 31,
			2016				As		Constant
	2016		(constant		2015		Reported		Currency %
($ in thousands)	(GAAP)		currency)		(GAAP)		% Change		Change⁽¹⁾

Advanced Wound Therapeutics revenue:
Rental	$	170,099	$	170,877	$	172,839	(1.6	)%	(1.1	)%
Sales	168,943		173,610		164,420		2.8		5.6
Total – Advanced Wound Therapeutics	339,042		344,487		337,259		0.5		2.1

Regenerative Medicine revenue:
Sales	109,874		110,172		104,169		5.5		5.8

Other revenue:
Sales	2,450		2,594		2,622		(6.6	)	(1.1	)

Total consolidated revenue:
Rental	170,099		170,877		172,839		(1.6	)	(1.1	)
Sales	281,267		286,376		271,211		3.7		5.6
Total consolidated revenue	$	451,366	$	457,253	$	444,050	1.6	%	3.0	%

(1) Represents percentage change between non-GAAP constant currency revenue and GAAP revenue from the prior year.

The following table sets forth, for the periods indicated, the percentage relationship of each item to total revenue in the period, as well as the changes in each line item:



	Three months ended March 31,
	2016		2015		Change

Advanced Wound Therapeutics revenue	75.2	%	76.0	%	(80	)	bps
Regenerative Medicine revenue	24.3	%	23.5	%	80		bps
Other revenue	0.5		0.5		—		bps
Total consolidated revenue	100.0	%	100.0	%

Rental revenue	37.7	%	38.9	%	(120	)	bps
Sales revenue	62.3		61.1		120		bps
Total consolidated revenue	100.0	%	100.0	%

AWT revenue for the first quarter of 2016 increased $1.8 million, or 0.5%, as reported on a GAAP basis, and $7.2 million, or 2.1%, on a constant currency basis, compared to the prior year period due to increased volumes in advance wound devices and strong Prevena sales. Foreign currency exchange rate movements unfavorably impacted AWT sales revenue by $4.7 million, or 2.8%, compared to the prior year period. Excluding the impact of foreign currency exchange rate movements, AWT sales revenue for the first quarter of 2016 increased $9.2 million, or 5.6%, compared to the prior year period due primarily to increased revenue from expansion products and growth internationally, partially offset by a decline in average pricing. Foreign currency exchange rate movements unfavorably impacted AWT rental revenue by $0.8 million, or 0.5%, compared to the prior year period. Excluding the impact of the foreign currency exchange rate movements, AWT rental revenue for the first quarter of 2016 decreased $2.0 million, or 1.1%, compared to the prior year period due to lower pricing, partially offset by increased rental volumes. Global AWT devices pricing and reimbursement declined approximately $8.1 million in the first quarter of 2016, compared to the prior year

period. Of this decline, approximately $3.5 million related to Medicare’s durable medical equipment competitive bidding program and the U.S. government’s sequestration, which further reduced Medicare pricing.

Regenerative Medicine revenue for the first quarter of 2016 increased $5.7 million, or 5.5%, as reported on a GAAP basis, and $6.0 million, or 5.8%, on a constant currency basis, compared to the prior year period. The increase in our Regenerative Medicine revenue was primarily driven by volume growth associated with an increase in the number of breast reconstruction procedures using our Regenerative Medicine products and strong Revolve sales, partially offset by decreases in the number of procedures using abdominal wall reconstruction products as some customers continue choosing lower cost synthetic alternatives for less complex procedures.

Other revenue for the first quarter of 2016 decreased $0.2 million, as reported on a GAAP basis, and was flat on a constant currency basis, compared to the prior year period. Other revenue consists of contract manufacturing revenue from our manufacturing plant in Gargrave, England.

Gross Profit and Gross Profit Margin

The following table presents the gross profit and gross profit margin (calculated as gross profit divided by total revenue for the periods indicated:



	Three months ended March 31,
($ in thousands)	2016			2015

Gross profit	$	297,892		$	292,458
Gross profit margin	66.0		%	65.9		%

Gross profit margin increased by 10 basis points to 66.0% in the first quarter of 2016 from 65.9% in the prior year period. The increase in the gross profit margin during the first quarter of 2016 compared to the prior year period was primarily due to improved production yields, primarily in our Regenerative Medicine business, partially offset by the impact of lower pricing associated with competitive bidding and the expansion of our distributor relationships in foreign countries, which yield lower gross margins.

Cost of sales for the first quarter of 2016 benefited from improved production yields, primarily in our Regenerative Medicine business. Foreign currency exchange rate movements favorably impacted cost of sales for the first quarter of 2016 by $1.4 million compared to the prior year period.

Rental expense for the first quarter of 2016 benefited from lower sales-related expenses associated with the decrease in rental revenue. Foreign currency exchange rate movements also favorably impacted rental expenses for the first quarter of 2016 by $1.1 million compared to the prior year period.

Selling, General and Administrative Expenses

The following table presents selling, general and administrative expenses (“SG&A”) and the percentage relationship to total revenue ~~for the periods indicated (dollars in thousands)~~:

	Three months ended September 30,									Nine months ended September 30,
	Three months ended March 31,
	2015			2014			Change			2015			2014			Change
($ in thousands)	2016			2015
Selling, general and administrative expenses	$	~~159~~164,~~956~~444		$	~~162~~147,~~269~~763		~~(1.4)%~~			$	~~466,713~~		$	~~507,646~~		~~(8.1)%~~
As a percent of total revenue	3336.54		%	33.73		%	~~(20~~	)	~~bps~~	~~33.7~~		%	~~36.7~~		%	~~(300~~	)	~~bps~~

~~Foreign currency exchange rate movements favorably impacted~~ SG&A expenses ~~during~~increased ~~the third quarter and first nine months of 2015~~ by $616.67 million ~~and~~in ~~$19.5~~the ~~million,~~first ~~respectively,~~quarter of 2016 compared to the prior year ~~periods~~period. ~~Excluding~~The ~~the impact of foreign currency exchange rate movements, the~~ increase in SG&A expenses ~~during~~for the ~~third~~first quarter of ~~2015~~2016 was ~~primarily~~ due primarily to ~~increased~~investments ~~incentive~~being ~~compensation~~made ~~expense~~in asour afranchise ~~result~~structure, ofsales ~~improved~~force ~~financial~~and ~~performance~~marketing ~~compared~~ to ~~the~~drive ~~prior~~growth, ~~year~~partially ~~period. Excluding~~offset ~~the~~by ~~impact of~~ foreign currency exchange rate movements, ~~the~~which ~~remaining~~favorably ~~decrease~~impacted in SG&A expenses ~~for~~during the first ~~nine~~quarter ~~months~~ of ~~2015~~2016 ~~was due primarily to lower selling-related costs and savings associated with our business optimization and integration efforts, partially offset~~ by ~~increased~~$2.6 ~~incentive~~million ~~compensation expense as a result of improved financial performance~~ compared to the prior year period.

Research and Development Expenses

The following table presents research and development expenses and the percentage relationship to total revenue ~~for the periods indicated (dollars in thousands)~~:

	Three months ended September 30,									Nine months ended September 30,
	Three months ended March 31,
	2015			2014			% Change			2015			2014			% Change
($ in thousands)	2016			2015
Research and development expenses	$	1413,~~271~~978		$	1514,~~879~~678		~~(10.1)%~~			$	~~43,340~~		$	~~51,602~~		~~(16.0)%~~
As a percent of total revenue	3.01		%	3.3		%	~~(30~~	)	~~bps~~	~~3.1~~		%	~~3.7~~		%	~~(60~~	)	~~bps~~

The decrease in R&D expenses is due primarily to lower salary-related expenses due to lower employee headcount. Expenses associated with product development, clinical studies and clinical research also decreased due to savings associated with our integration efforts.

Acquired Intangible Asset Amortization

We have recorded identifiable intangible assets in connection with the 2011 ~~merger~~LBO, the 2013 Systagenix acquisition and various technology acquisitions. During the ~~third~~first quarters of ~~2015~~2016 and ~~2014~~2015, we recorded $4342.82 million and $4745.9 million, respectively, of amortization expense associated with these identifiable intangible assets. ~~During the first nine months of 2015 and 2014, we recorded $134.4 million and $147.4 million, respectively, of amortization expense associated with these identifiable intangible assets.~~

Wake Forest Settlement

On June 30, 2014 , KCI entered into a settlement and release agreement (the “Settlement Agreement”) with Wake Forest to fully and finally resolve the pending patent disputes between them regarding Wake Forest’s NPWT patents formerly licensed to KCI. To fully resolve all the pending disputes between KCI and Wake Forest, KCI agreed to pay Wake Forest retrospective U.S. patent royalties in the amount of $280 million, according to the following schedule: $80 million paid in July 2014, $85 million paid in June 2015, $85 million to be paid in June 2016, and $30 million to be paid in June 2017. As a result, we recorded patent settlement charges of $198.6 million in the second quarter of 2014 representing the net present value of payments under the Settlement Agreement, net of the $63.2 million previously existing accrual.

Interest Expense

Interest expense increased to $~~106~~108.6 million ~~and $318.7 million~~ in the ~~third~~first quarter ~~and first nine months~~ of ~~2015,~~2016 ~~respectively,~~ compared to $104.57 million ~~and $308.5 million~~ in the prior- year ~~periods~~period due to ~~accretion~~higher ofinterest ~~the~~rates ~~Wake~~associated ~~Forest~~with ~~settlement~~our ~~liability~~Senior ~~related~~Secured toCredit ~~the~~Facilities ~~Settlement Agreement~~ and ~~higher~~the ~~interest~~addition ~~rates~~of ~~associated~~our ~~with~~$7.875% ~~Amendment~~First ~~No.~~Lien 6Senior ofSecured ~~our~~Notes, ~~existing~~partially ~~senior~~offset ~~secured~~by ~~credit~~the ~~facilities~~repayment ~~which~~in wefull ~~entered~~of ~~into~~our onSenior ~~March~~Term ~~10,~~E-2 ~~2015~~Credit Facility.

Foreign Currency Gain (Loss)

Foreign currency ~~transactions~~transaction ~~resulted in a~~ loss ofwas $94.~~2 million and a gain of $~~3.4 million during the ~~third~~first quarter ~~and first nine months~~ of ~~2015,~~2016 ~~respectively,~~ compared to ~~gains~~a gain of $919.64 million ~~and~~during ~~$13.7~~the ~~million~~first inquarter ~~the~~of ~~prior-year periods~~2015. The revaluation of the Term E-1 EURO loan to U.S. dollars represented a foreign currency transaction loss of $012.63 million ~~and gain of $22.4 million~~ during the ~~third~~first quarter ~~and first nine months~~ of ~~2015,~~2016 ~~respectively. The~~compared ~~revaluation of the Term E-1 EURO loan~~ to ~~U.S.~~a ~~dollars~~gain ~~represented foreign currency transaction gains~~ of $2432.54 million ~~and~~ ~~$27.6 million~~ in the prior- year ~~periods~~period. Excluding the revaluation of the Term E-1 EURO loan to U.S. dollars, we recognized foreign currency exchange ~~losses~~gains of $8.~~6 million and $19.~~0 million during the ~~third~~first quarter ~~and first nine months~~ of ~~2015,~~2016 ~~respectively,~~ compared to ~~losses~~a loss of $~~14.9 million and $~~13.90 million in the prior- year ~~periods~~period due to significant fluctuations in the Euro exchange rate.

Derivative Instruments Loss

During the ~~third~~first quarter ~~and first nine months~~ of ~~2015~~2016, we recorded a derivative instruments loss of $0.97 million ~~and~~due ~~$5.1~~primarily ~~million,~~to ~~respectively,~~fluctuations ~~compared~~in tothe avalue ~~gain~~ of ~~$1.6~~our ~~million~~interest ~~and~~rate aderivative ~~loss of $2~~instruments.7 During ~~million of in~~ the ~~comparable~~first ~~prior-year~~quarter ~~periods~~of ~~due~~2015, ~~primarily to fluctuations in~~ the ~~value~~derivative ofinstruments ~~our~~loss ~~interest~~was ~~rate~~$3.3 ~~derivative instruments~~million.

Income Tax Expense (Benefit)

~~The~~During ~~income tax benefit from continuing operations decreased by $1.0 million to $0.6 million for~~ the ~~three~~first ~~months~~quarter ~~ended~~of ~~September 30~~2016, ~~2015,~~we ~~compared~~recorded toan ~~$1.6 million in the comparable prior year period. The~~ income tax benefit ~~from~~of ~~continuing operations decreased by~~ $~~106~~13.48 million compared to ~~$7.7~~income ~~million~~tax ~~for~~expense ~~the~~of ~~nine months ended September 30, 2015, compared to~~ $~~114~~0.1 million in the comparable prior year period. The ~~decreased~~ income tax benefit was primarily due to ~~lower~~higher pretax losses in the first ~~nine~~quarter ~~months~~ of ~~2015~~2016.

Earnings from Discontinued Operations

No gains or losses from discontinued operations were recorded in the third quarter and first nine months of 2015. During the third quarter and first nine months of 2014, we recorded a gain from discontinued operations, net of tax, of $1.4 million and $3.2 million, respectively, related to the disposition of our SPY assets.

Net Loss

Net loss increased by $821.25 million to $1026.0 million for the ~~third~~first quarter of ~~2015~~2016, compared to $14.85 million in the prior year period. The increase was primarily due to ~~the~~ $94.23 million of foreign currency ~~loss~~losses incompared ~~the~~to ~~third~~foreign ~~quarter~~currency gains of ~~2015, compared to the~~ $919.64 million ~~gain~~ in the prior year period. Also ~~Net~~contributing ~~loss~~to ~~decreased~~the byhigher ~~$168.8~~net ~~million~~loss toin ~~$32.1 million for~~ the first ~~nine~~quarter ~~months~~ of ~~2015,~~2016 ~~compared~~were tothe ~~$200.9~~increased ~~million~~investments made in ~~the~~our ~~prior~~franchise ~~year~~structure, ~~period.~~sales ~~The~~force ~~improvement~~and ~~was~~marketing ~~primarily due~~ to ~~the~~drive ~~$301.3~~growth, ~~million~~partially ~~improvement~~offset ~~in operating earnings driven~~ by ~~the~~revenue ~~improved~~growth ~~operating performance described above~~ and ~~the~~expense ~~absence~~savings ofassociated awith ~~$198.6~~our ~~million~~integration ~~litigation-related~~and ~~charge~~business ~~related~~optimization ~~to the Settlement Agreement~~efforts.

LIQUIDITY AND CAPITAL RESOURCES

General

Our primary uses of cash are working capital requirements, capital expenditures and debt service requirements. Additionally, from time to time, we may use capital for acquisitions and other investing and financing activities. Working capital is required principally to finance accounts receivable and inventory. Our working capital requirements vary from period-to-period depending on manufacturing volumes, the timing of shipments and the payment cycles of our customers and payers. Our capital expenditures consist primarily of manufactured rental assets, manufacturing equipment, computer hardware and software, expenditures related to leasehold improvements and expenditures related to our global corporate headquarters building.

33Historically, our primary source of liquidity has been cash flow from operations. In addition, we also have a $200.0 million Revolving Credit Facility to provide us with an additional source of liquidity. We anticipate that cash generated from operations together with amounts available under our Revolving Credit Facility will be sufficient to meet our future working capital requirements, capital expenditures and debt service obligations as they become due for the foreseeable future. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. In the event that we need access to additional cash, we may not be able to access the credit markets on commercially acceptable terms or at all. Our ability to fund future operating expenses and capital expenditures and our ability to meet future debt service obligations or refinance our indebtedness will depend on our future operating performance which will be affected by general economic, financial and other factors beyond our control, including those described under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

~~Historically,~~As ~~our primary source~~ of ~~liquidity~~March 31, ~~has~~2016, ~~been~~our cash ~~flow~~and ~~from~~cash ~~operations.~~equivalents Inwere ~~addition, we also have a~~ $~~200~~223.06 million ~~revolving credit facility to provide us with an additional source of liquidity~~. We ~~anticipate~~are ~~that~~highly ~~cash~~leveraged. ~~generated~~As ~~from~~of ~~operations~~March 31, ~~together~~2016, ~~with~~we ~~amounts~~had ~~available~~approximately ~~under~~$4.8 ~~our~~billion ~~revolving~~of ~~credit~~aggregate ~~facility~~principal ~~will~~amount beof ~~sufficient~~indebtedness ~~to meet our future working capital requirements~~outstanding, ~~capital~~with ~~expenditures~~an ~~and~~additional ~~debt service obligations as they become due for the foreseeable future~~$162.1 Tomillion ~~the~~of ~~extent~~unused ~~additional~~commitments ~~funds~~available ~~are necessary~~ to ~~meet~~be ~~our~~borrowed ~~long-term~~under ~~liquidity needs as we continue to execute~~ our ~~business~~Revolving ~~strategy,~~Credit weFacility. ~~anticipate~~We ~~that~~also ~~they~~can ~~will~~incur ~~be obtained through the incurrence of~~ additional indebtedness, ~~additional~~including ~~equity~~secured ~~financings~~indebtedness, orif acertain ~~combination~~specified ofconditions ~~these~~are ~~potential~~met ~~sources~~under ~~of funds. In~~ the ~~event~~credit ~~that~~agreement wegoverning ~~need~~the ~~access~~Senior toSecured ~~additional~~Credit ~~cash,~~Facilities weand ~~may~~the ~~not~~indentures begoverning ~~able to access~~ the ~~credit~~outstanding ~~markets on commercially acceptable terms or at all~~notes. Our ~~ability~~liquidity torequirements ~~fund~~will ~~future~~be ~~operating~~significant, ~~expenses~~primarily ~~and~~due ~~capital expenditures and our ability~~ to ~~meet future~~ debt service obligations or refinance our indebtedness will depend on our future operating performance which will be affected by general economic, financial and other factors beyond our control, including those described under “Risk Factorsrequirements.”

The following table presents our cash and cash equivalents and debt as of the date indicated (in thousands):

	September 30, 2015		December 31, 2014		Change
Cash and cash equivalents	$	197,010	$	183,541	$	13,469
Total debt (1)	4,806,646		4,841,975		(35,329		)

(1) Total debt equals current and long-term debt, net of discount, and capital lease obligations.

As of September 30, 2015, our cash and cash equivalents were $197.0 million. As of September 30, 2015, no revolving credit loans were outstanding under our Revolving Credit Facility, $38.3 million of letters of credit issued by banks party to our senior secured credit facilities were outstanding (reducing the availability under the Revolving Credit Facility to $161.7 million) and $8.8 million of letters of credit issued by a bank not party to our senior secured credit facilities were outstanding. The decrease in our total debt as of September 30, 2015 as compared to December 31, 2014 was primarily due to scheduled payments on our senior secured credit facilities.

We and our Sponsors may from time to time seek to retire or purchase our outstanding debt through cash purchases, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Cash Flows

The following table summarizes the net cash provided (used) by operating activities, investing activities and financing activities for the periods indicated ~~(in thousands)~~:

	Nine months ended September 30,
	Three months ended March 31,
	2015			2014
($ in thousands)	2016			2015
Net cash provided by operating activities	$	~~110~~78,~~010~~185		$	~~105~~102,~~031~~951
Net cash used by investing activities	(5419,~~757~~577		)	(6115,~~762~~668		)
Net cash used by financing activities	(33,495		)	(21,279		)
Net cash provided (used) by financing activities	73,645			(13,243		)
Effect of exchange rate changes on cash and cash equivalents	2,954			(7,072		)
Net increase in cash and cash equivalents	$	135,207		$	66,968

Operating Activities

For the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September 30~~2016, ~~2015,~~ net cash provided by operating activities was $~~110~~78.02 million, compared to net cash provided by operating activities of $~~105~~103.0 million for the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September 30, 2014~~2015. The ~~Net~~decrease in cash provided by operations ~~for the first nine months of 2015 and 2014~~ was ~~impacted~~primarily driven by ~~Wake~~higher ~~Forest~~working ~~settlement~~capital ~~payments of $85~~requirements.0 ~~million and $80.0 million, respectively.~~

Investing Activities

For the first ~~nine~~quarter ~~months~~of ~~ended September 30~~2016, ~~2015,~~ net cash used by investing activities was $5419.86 million, compared to $6115.87 million for the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September 30, 2014~~2015. Net cash used by investing activities was higher during the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September~~2016 ~~30, 2014~~ due to higher ~~expenditures~~capital ~~on patents and trademarks as well as $4~~expenditures.~~5 million spent in connection with our acquisition of Attenuate in January 2014, partially offset by the $2.9 million spent in connection with our acquisition of a Brazilian distributor in June 2015.~~

Financing Activities

For the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September 30~~2016, ~~2015,~~ net cash ~~used~~provided by financing activities was $3373.56 million, compared to net cash used by financing activities of $2113.32 million for the ~~nine~~first ~~months~~quarter ~~ended~~of ~~September 30, 2014~~2015. Net cash ~~used~~provided by financing activities increased primarily due to the proceeds from the issuance of $6400.30 million aggregate principal amount of ~~expenses~~7.875% inFirst ~~March~~Lien ~~2015~~Senior ~~related~~Secured toNotes net of the ~~credit~~repayment ~~facility~~of ~~amendment~~all amounts outstanding under our Senior Term E-2 Credit Facility.

Discontinued Operations

Cash flows related to discontinued operations were not material for the nine months ended September 30, 2015 and 2014, and therefore have not been separately disclosed in our condensed consolidated statements of cash flows. We do not anticipate the absence of cash flows from discontinued operations to significantly affect our liquidity and capital resources.

Capital Expenditures

During the first ~~nine~~quarters ~~months~~ of ~~2015~~2016 and ~~2014~~2015, we made capital expenditures of $4617.15 million and $4610.85 million, respectively. Capital expenditures during the first ~~nine~~quarters ~~months~~ of ~~2015~~2016 and ~~2014~~2015 related primarily to expanding the rental fleet and information technology projects and purchases.

Debt

~~Existing~~ Senior Secured Credit Facilities

~~The~~On ~~following~~November 4, ~~table~~2011, ~~sets~~Kinetic ~~forth~~Concepts, ~~the~~Inc. ~~amounts~~and ~~owed~~its ~~under~~subsidiary, KCI USA, Inc., as co-borrowers, or collectively, the ~~Existing~~Borrowers, Acelity L.P. Inc., Chiron Holdings, Inc. and Chiron Topco, Inc. and, with respect to certain representations and warranties, Chiron Guernsey GP Co. Limited, entered into a credit agreement, or the Senior Secured Credit Facilities, ~~the~~with ~~effective~~Bank ~~interest~~of ~~rates~~America, onN.A., ~~such~~as ~~outstanding~~administrative ~~amounts~~and collateral agent, Morgan Stanley Senior Funding, Inc. and ~~the~~Credit ~~amount~~Suisse ~~available~~Securities ~~for~~(USA) ~~additional~~LLC, ~~borrowing~~as ~~thereunder~~syndication agents, Royal Bank of Canada, as documentation agent, UBS Securities LLC, as co-manager, Bank of ~~September~~America, N.A., Morgan Stanley Senior Funding, Inc., Credit Suisse Securities (USA) LLC and RBC Capital Markets, LLC, as joint lead arrangers and bookrunners, and the lenders party thereto from time to time. The Senior Secured Credit Facilities were amended on November 307, 2012, June 14, 2013, October 28, 2013, November 15, 2013, January 22, 2014, and March 10, 2015, ~~(dollars~~to, inamong ~~thousands):~~other things, reduce the overall pricing and amend the financial covenants of the Senior Secured Credit Facilities. The Senior Secured Credit Facilities were also amended on February 9, 2016, to, among other things, extend the maturity date of certain lenders’ commitments under the Revolving Credit Facility. After giving effect to the February 2016 amendments, we continue to have $200 million of aggregate revolving loan commitments under our Revolving Credit Facility with $28.7 million of the commitments maturing on November 4, 2016, and $171.3 million maturing on November 4, 2017.

Senior Secured Credit Facility	MaturityDate	EffectiveInterestRate			AmountOutstanding (1)		Amount Availablefor AdditionalBorrowing
Senior Revolving Credit Facility	November 2016	—	%		$	—	$	161,695	(2)
Senior Dollar Term E-1 Credit Facility	May 2018	5.00	%	(3)	1,889,749		—
Senior Euro Term E-1 Credit Facility	May 2018	5.67	%	(3)	262,856		—
Senior Term E-2 Credit Facility	November 2016	4.69	%	(3)	310,678		—
Total					$	2,463,283	$	161,695

The following table sets forth the amounts owed under the Senior Secured Credit Facilities, the effective interest rates on such outstanding amounts, and the amount available for additional borrowing thereunder, as of March 31, 2016 (dollars in thousands):



Senior Secured Credit Facilities	Maturity Date		Effective Interest Rate			Amount Outstanding⁽¹⁾		Amount Available for Additional Borrowing
Senior Revolving Credit Facility	November 2016 November 2017	⁽²⁾	—	%		$	—	$	162,061	⁽²⁾⁽³⁾
Senior Dollar Term E-1 Credit Facility	May 2018		5.00	%	⁽⁴⁾	1,884,237		—
Senior Euro Term E-1 Credit Facility	May 2018		5.67	%	⁽⁴⁾	267,865		—
Total						$	2,152,102	$	162,061

_____________________


(1)	Amount outstanding includes the original issue discount.

(2) AtAfter ~~September~~giving ~~30,~~effect ~~2015~~to Amendment No. 7 and Amendment No. 8, ~~the~~we ~~amount~~have ~~available~~aggregate revolving loan commitments under the Revolving Credit Facility ~~reflected a reduction~~ of $38171.3 million ofmaturing ~~letters~~on ofNovember ~~credit~~4, ~~issued by banks which are party to the Existing Senior Secured Credit Facilities. In addition~~2017, wewith ~~have~~an additional $828.87 million ofin ~~letters~~revolving ofloan ~~credit~~commitments ~~issued~~continuing ~~by a bank not party~~ to ~~the~~mature ~~Existing~~on ~~Senior~~November ~~Secured~~4, ~~Credit Facilities~~2016.

(3) ~~The~~At ~~effective~~March ~~interest~~31, ~~rate~~2016, ~~includes~~ the ~~effect~~amount ofavailable under the ~~original~~Revolving ~~issue~~Credit ~~discount.~~Facility ~~Excluding~~reflected ~~the~~a ~~original~~reduction ~~issue~~of ~~discount,~~$37.9 ~~our~~million ~~nominal~~of ~~interest~~letters ~~rate~~of ascredit ofissued ~~September~~by ~~30,~~banks ~~2015~~which ~~was~~are ~~4.50%~~party onto the Senior ~~Dollar~~Secured ~~Term~~Credit ~~E-1~~Facilities. ~~Credit~~In ~~Facility~~addition, 4we have $7.~~75%~~7 onmillion ~~the~~of ~~Senior~~letters ~~Euro~~of ~~Term~~credit ~~E-1~~issued ~~Credit~~by ~~Facility~~a ~~and~~bank ~~4.00%~~not onparty to the Senior ~~Term~~Secured ~~E-2~~ Credit ~~Facility~~Facilities.

On(4) ~~March~~The ~~10,~~effective ~~2015,~~interest werate ~~entered~~includes ~~into~~the ~~Amendment~~effect ~~No.~~of ~~6 to~~ the ~~Existing~~original ~~Senior~~issue ~~Secured Credit Facilities (“Amendment No~~discount. ~~6”). In~~Excluding ~~connection~~the ~~with~~original ~~Amendment~~issue ~~No. 6~~discount, ~~certain~~our ~~applicable~~nominal ~~rates were modified such that (i) Dollar Term E-1 Loans bear~~ interest ~~at a~~ rate ~~equal~~as ~~to,~~of atMarch ~~KCI’s election~~31, a2016 ~~Eurocurrency~~was ~~rate plus 3~~4.50% oron anthe ~~adjusted~~Senior ~~base~~Dollar ~~rate plus 2.50%, (ii) Euro~~ Term E-1 ~~Loans~~Credit ~~bear~~Facility ~~interest~~and ~~at a rate equal to, at KCI’s election, a Eurocurrency rate plus 3~~4.75% oron an adjusted base rate plus 2.75%, and (iii) Term E-2 Loans bear interest at a rate equal to, at KCI’s election, a Eurocurrency rate plus 3.00% or an adjusted base rate plus 2.00%. The Eurocurrency rate shall be subject to a floor of 1.00%, and the ~~adjusted~~Senior ~~base rate shall be subject to a floor of 2.00%. Repayments of Dollar Term E-1 Loans,~~ Euro Term E-1 ~~Loans~~Credit ~~or Term E-2 Loans within 12 months of the effective date of Amendment No~~Facility. 6 in connection with a repricing transaction will be subject to a 1.0% prepayment premium. As a result of Amendment No. 6, the financial covenants were amended to remove the interest coverage ratio in its entirety and to set the total leverage ratio for any test period to be no greater than 8.25:1.00. In addition, certain other covenants were amended, including with respect to the incurrence of incremental facilities and asset sales.

3538

10.5% Second Lien Senior Secured Notes and 12.5% Senior Unsecured Notes

In ~~November~~connection with the 2011 LBO, weon ~~issued~~November 4, ~~$1.750~~2011, ~~billion~~Kinetic ~~aggregate~~Concepts, ~~principal~~Inc. ~~amount~~and ofits ~~second~~subsidiary, ~~lien~~KCI ~~senior~~USA, ~~secured~~Inc., ~~notes~~or ~~due~~collectively, ~~2018 (~~the ~~“10.5%~~Existing ~~Second Lien~~ Notes~~”).~~ ~~Interest~~Issuers, onco-issued ~~the 10~~$1.5%750 ~~Second~~billion ~~Lien~~aggregate ~~Notes~~principal ~~accrues~~amount ~~at the rate~~ of 10.5% ~~per~~Second ~~annum~~Lien ~~and~~Senior isSecured ~~payable~~Notes ~~semi-annually~~due in2018, ~~cash~~or onthe ~~each~~Second ~~May 1~~Lien Notes, and ~~November 1~~$750.0 ~~through~~million ~~the~~aggregate ~~maturity~~principal ~~date. The~~amount 10of 12.5% ~~Second~~Senior ~~Lien~~Unsecured Notes ~~were~~due ~~issued~~2019, ator athe ~~discount~~Unsecured ~~resulting in an effective interest rate of 10~~Notes.~~87%.~~

12As of March 31, 2016, we had outstanding $1,735.5% ~~Senior~~million aggregate principal amount, net of discount of $14.5 million (net of accretion), of the Second Lien Notes and $609.9 million aggregate principal amount, net of discount of $2.1 million (net of accretion), of the Unsecured Notes.

~~In November 2011, we issued $750.0 million aggregate principal amount of senior unsecured notes due 2019 (the “12.5% Unsecured Notes”); $612.0 million of which are still outstanding.~~ Interest on the ~~12.5%~~Second ~~Unsecured~~Lien Notes accrues at the rate of 1210.50% per annum and is payable semi-annually in cash on each May 1 and November ~~1through~~1 to the ~~maturity~~persons who are registered holders at the close of business on April 15 and October 15 immediately preceding the applicable interest payment date. The ~~12.5%~~Second ~~Unsecured~~Lien Notes were issued at a discount resulting in an effective interest rate of 1210.6287%.

Interest on the Unsecured Notes accrues at the rate of 12.50% per annum and is payable semi-annually in cash on each May 1 and November 1 to the persons who are registered holders at the close of business on April 15 and October 15 immediately preceding the applicable interest payment date. The Unsecured Notes were issued at a discount resulting in an effective interest rate of 12.62%.

7.875% First Lien Senior Secured Notes

On February 9, 2016, the Existing Notes Issuers co-issued $400.0 million aggregate principal amount of 7.875% First Lien Senior Secured Notes due 2021, or the First Lien Notes. Interest on the First Lien Notes accrues at the rate of 7.875% per annum and is payable semi-annually in arrears on each February 15 and August 15, beginning on August 15, 2016, to the persons who are registered holders at the close of business on February 1 and August 1 immediately preceding the applicable interest payment date. The First Lien Notes were issued at par. The First Lien Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by Acelity L.P. Inc., Chiron Topco, Inc., Chiron Holdings, Inc., LifeCell Corporation and each of Acelity L.P. Inc.’s other subsidiaries to the extent such entities guarantee indebtedness under the Senior Secured Credit Facilities or the Second Lien Notes and Unsecured Notes. The First Lien Notes and related guarantees are initially secured on a first-priority basis by security interests in all of the Existing Notes Issuers’ and the guarantors’ assets that secure our Senior Secured Credit Facilities on a first-priority basis. The First Lien Notes and related guarantees will not be registered for resale under the Securities Act of 1993, as amended, or the Securities Act, or the securities laws of any other jurisdiction or offered to be exchanged for registered notes under the Securities Act or securities laws of any other jurisdiction. On or after February 15, 2018, the Existing Notes Issuers may redeem some or all of the First Lien Notes at redemption prices (expressed as percentages of the principal amount) equal to 103.938% through February 14, 2019, 101.969% from February 15, 2019 through February 14, 2020, and at par thereafter, plus accrued and unpaid interest, if any, to the redemption date.

Covenants

AsThe credit agreement governing the Senior Secured Credit Facilities and the indentures governing the First Lien Notes, Second Lien Notes and Unsecured Notes contain a number of ~~September 30~~covenants that, ~~2015~~among other things, werestrict, ~~were~~subject to certain exceptions, our ability to incur or guarantee additional indebtedness; create liens on assets; engage in ~~compliance~~mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with ~~all~~affiliates; ~~covenants~~make ~~under~~investments, loans or advances; make certain acquisitions; and in the case of the credit agreement governing the Senior Secured Credit Facilities, change our lines of business. The credit agreement governing the Senior Secured Credit Facilities and the indentures. governing the First Lien Notes, Second Lien Notes and Unsecured Notes also contain change of control provisions and certain customary covenants and events of default.

~~For~~As ~~further~~of ~~information~~March 31, on2016, ~~our~~we ~~long-term~~were ~~debt,~~in ~~see~~compliance ~~Note~~with 5all ofcovenants under the ~~notes~~credit toagreement governing the ~~consolidated~~Senior ~~financial~~Secured ~~statements~~Credit ~~included~~Facilities inand ~~our~~the ~~Annual~~indentures ~~Report~~governing onthe ~~Form~~Existing ~~10-K~~Notes ~~for~~and the ~~fiscal~~First ~~year~~Lien ~~ended December 31, 2014~~Notes.

For further information on our long-term debt, see Note 4 of the notes to the condensed consolidated financial statements included herein and Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Interest Rate Protection

At ~~September~~March 3031, ~~2015~~2016, and December 31, ~~2014~~2015, we were party to three interest rate swap agreements to convert $1.~~436~~378 billion and $1.~~463~~380 billion, respectively, of our outstanding variable rate debt to a fixed rate basis. The aggregate notional amount of the interest rate swaps decreases quarterly by amounts ranging from $1.7 million to $561.48 million until maturity. ~~Our~~As of March 31, 2016, these interest rate protection agreements have not been designated as hedging instruments, and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period.

In April 2016, we entered into three additional interest rate swap agreements to convert $1.165 billion of our variable-rate debt to a fixed-rate basis, which become effective in December 2016. These agreements have been designated as cash flow hedge instruments. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $4.4 million to $84.5 million until maturity.

For further information on our interest rate protection agreements, see Note 5 of the notes to the condensed consolidated financial statements.

Contractual Obligations

There have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations since December 31, ~~2014~~2015.

Critical Accounting Estimates

For a description of our critical accounting estimates, please see our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015 under the heading Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates."

Recently Issued Accounting Standards

See note 1(e) of the notes to condensed consolidated financial statements included in this report for a discussion of recently issued accounting standards.

3640

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, including fluctuations in interest rates and variability in currency exchange rates. There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015. For a description of our policies, procedures and internal processes governing our management of market risk and the use of financial instruments to manage our exposure to such risk, please see our Annual Report for the fiscal year ended December 31, ~~2014~~2015 under the heading “Quantitative and Qualitative Disclosures About Market Risk.”

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures. Our management, with the participation of the principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. There have not been any changes in our internal control over financial reporting (as such term is defined by paragraph (df) of Rule 13a-15) under the Exchange Act, during the ~~third~~first fiscal quarter of ~~2015~~2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Incorporated in this Item 1, by reference, are the legal proceedings described in Note 7 of the notes to condensed consolidated financial statements included in this report under the heading "Commitments and Contingencies: Legal Proceedings."

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ~~2014~~2015.

3741

ITEM 6. EXHIBITS

A list of all exhibits filed or included as part of this quarterly report on Form 10-Q is as follows:
Exhibit Number	Description	~~Description~~
3.1	Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).	~~Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).~~
3.2	Certificate of Registration of Acelity L.P. Inc. (filed as Exhibit 3.2 to our Form 10-Q for the quarterly period ended September 30, 2014).	~~Certificate of Registration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.4 to our Registration Statement on Form S-4 filed on October 1, 2012).~~
3.3	Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).	~~Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).~~
†31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
4.1	Indenture, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., the guarantors party thereto and Wilmington Trust, N.A., as trustee and as collateral agent (filed as Exhibit 4.1 to our Form 8-K filed on February 10, 2016).
†31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
4.2	Form of 7.875% First Lien Senior Secured Notes due 2021 (included as Exhibit A to Exhibit 4.1).
†32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
10.1	Amendment No. 7 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on February 10, 2016).
		† Exhibit filed herewith.
10.2	Amendment No. 8 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.2 to our Form 8-K filed on February 10, 2016).
*†10.3	Third Amended and Restated Chiron Guernsey Holdings L.P. Inc. Executive Equity Incentive Plan.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†100	Interactive data files.
	† Exhibit filed herewith.
	* Compensatory arrangements for director(s) and/or executive officer(s).

3842

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Antonio, State of Texas on ~~October~~May 283, ~~2015~~2016.

	ACELITY L.P. INC.
	(REGISTRANT)
Date: October 28, 2015	By:	/s/ Joseph F. Woody
Date: May 3, 2016	By:	/s/ Joseph F. Woody
		Joseph F. Woody
		Principal Executive Officer
		(Duly Authorized Officer)
Date: October 28, 2015	By:	/s/ Thomas W. Casey
Date: May 3, 2016	By:	/s/ Thomas W. Casey
		Thomas W. Casey
		Principal Financial Officer
		(Duly Authorized Officer)

3943

EXHIBITS

Exhibit Number	Description	~~Description~~
3.1	Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).	~~Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).~~
3.2	Certificate of Registration of Acelity L.P. Inc. (filed as Exhibit 3.2 to our Form 10-Q for the quarterly period ended September 30, 2014).	~~Certificate of Registration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.4 to our Registration Statement on Form S-4 filed on October 1, 2012).~~
3.3	Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).	~~Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).~~
†31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
4.1	Indenture, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., the guarantors party thereto and Wilmington Trust, N.A., as trustee and as collateral agent (filed as Exhibit 4.1 to our Form 8-K filed on February 10, 2016).
†31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
4.2	Form of 7.875% First Lien Senior Secured Notes due 2021 (included as Exhibit A to Exhibit 4.1).
†32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated October 28, 2015.
10.1	Amendment No. 7 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on February 10, 2016).
		† Exhibit filed herewith.
10.2	Amendment No. 8 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.2 to our Form 8-K filed on February 10, 2016).
*†10.3	Third Amended and Restated Chiron Guernsey Holdings L.P. Inc. Executive Equity Incentive Plan.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†100	Interactive data files.
	† Exhibit filed herewith.
	* Compensatory arrangements for director(s) and/or executive officer(s).

4044

Filing Compare · Acelity L.P. Inc.